: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

Oliena Studio

Stroke and language recovery: 9000+ videos

Español • Italiano • Sardu • English | PDF+

Multiple Sclerosis

Free Subscription

Articles published in Mult Scler
Retrieve available abstracts of 546 articles:
HTML format
Text format

Single Articles

October 2019

BIANCHI A, Ciccarelli O
Daclizumab-induced encephalitis in multiple sclerosis.
Mult Scler. 2019;25:1557-1559.
PubMed Text format

IGHANI M, Jonas S, Izbudak I, Choi S, et al
No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis.
Mult Scler. 2019 Oct 1:1352458519876037. doi: 10.1177/1352458519876037.
PubMed Text format Abstract available

GRYTTEN N, Myhr KM, Celius EG, Benjaminsen E, et al
Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study.
Mult Scler. 2019 Oct 1:1352458519877244. doi: 10.1177/1352458519877244.
PubMed Text format Abstract available

ZECCA C, Bovis F, Novi G, Capobianco M, et al
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
Mult Scler. 2019 Oct 1:1352458519872889. doi: 10.1177/1352458519872889.
PubMed Text format Abstract available

September 2019

PALOTAI M, Guttmann CR
Brain anatomical correlates of fatigue in multiple sclerosis.
Mult Scler. 2019 Sep 19:1352458519876032. doi: 10.1177/1352458519876032.
PubMed Text format Abstract available

MAGGI P, Absinta M, Sati P, Perrotta G, et al
The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study.
Mult Scler. 2019 Sep 19:1352458519876031. doi: 10.1177/1352458519876031.
PubMed Text format Abstract available

MARRIE RA, Tremlett H, Kingwell E, Schaffer SA, et al
Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study.
Mult Scler. 2019 Sep 13:1352458519876038. doi: 10.1177/1352458519876038.
PubMed Text format Abstract available

VAN GEEL F, Veldkamp R, Severijns D, Dalgas U, et al
Day-to-day reliability, agreement and discriminative validity of measuring walking-related performance fatigability in persons with multiple sclerosis.
Mult Scler. 2019 Sep 9:1352458519872465. doi: 10.1177/1352458519872465.
PubMed Text format Abstract available

BRANDSTADTER R, Katz Sand I, Sumowski JF
Beyond rehabilitation: A prevention model of reserve and brain maintenance in multiple sclerosis.
Mult Scler. 2019;25:1372-1378.
PubMed Text format Abstract available

WEBER E, Goverover Y, DeLuca J
Beyond cognitive dysfunction: Relevance of ecological validity of neuropsychological tests in multiple sclerosis.
Mult Scler. 2019;25:1412-1419.
PubMed Text format Abstract available

August 2019

PALOTAI M, Cavallari M, Koubiyr I, Morales Pinzon A, et al
Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression.
Mult Scler. 2019 Aug 16:1352458519869185. doi: 10.1177/1352458519869185.
PubMed Text format Abstract available

FAMBIATOS A, Jokubaitis V, Horakova D, Kubala Havrdova E, et al
Risk of secondary progressive multiple sclerosis: A longitudinal study.
Mult Scler. 2019 Aug 9:1352458519868990. doi: 10.1177/1352458519868990.
PubMed Text format Abstract available

PISA M, Ratti F, Vabanesi M, Radaelli M, et al
Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography.
Mult Scler. 2019 Aug 8:1352458519861603. doi: 10.1177/1352458519861603.
PubMed Text format Abstract available

SIVAKOLUNDU DK, West KL, Maruthy GB, Zuppichini M, et al
Reduced arterial compliance along the cerebrovascular tree predicts cognitive slowing in multiple sclerosis: Evidence for a neurovascular uncoupling hypothesis.
Mult Scler. 2019 Aug 2:1352458519866605. doi: 10.1177/1352458519866605.
PubMed Text format Abstract available

HERRANZ E, Louapre C, Treaba CA, Govindarajan ST, et al
Profiles of cortical inflammation in multiple sclerosis by (11)C-PBR28 MR-PET and 7 Tesla imaging.
Mult Scler. 2019 Aug 1:1352458519867320. doi: 10.1177/1352458519867320.
PubMed Text format Abstract available

MCGINLEY MP, Cola PA, Fox RJ, Cohen JA, et al
Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies.
Mult Scler. 2019 Aug 1:1352458519867314. doi: 10.1177/1352458519867314.
PubMed Text format Abstract available

BOVE R, Rankin K, Lin C, Zhao C, et al
Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis.
Mult Scler. 2019 Aug 1:1352458519865118. doi: 10.1177/1352458519865118.
PubMed Text format Abstract available

BEECHAM AH, Amezcua L, Chinea A, Manrique CP, et al
The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States.
Mult Scler. 2019 Aug 1:1352458519863764. doi: 10.1177/1352458519863764.
PubMed Text format Abstract available

July 2019

SOTIRCHOS ES, Filippatou A, Fitzgerald KC, Salama S, et al
Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning.
Mult Scler. 2019 Jul 31:1352458519864928. doi: 10.1177/1352458519864928.
PubMed Text format Abstract available

SCHWEHR NA, Kuntz KM, Butler M, Enns EA, et al
Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis.
Mult Scler. 2019 Jul 29:1352458519866613. doi: 10.1177/1352458519866613.
PubMed Text format Abstract available

CAMPBELL JA, Simpson S Jr, Ahmad H, Taylor BV, et al
Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data.
Mult Scler. 2019 Jul 26:1352458519861270. doi: 10.1177/1352458519861270.
PubMed Text format Abstract available

LARSSON D, Akerfeldt T, Carlson K, Burman J, et al
Intrathecal immunoglobulins and neurofilament light after autologous haematopoietic stem cell transplantation for multiple sclerosis.
Mult Scler. 2019 Jul 26:1352458519863983. doi: 10.1177/1352458519863983.
PubMed Text format Abstract available

PRAVATA E, Valsasina P, Gobbi C, Zecca C, et al
Influence of CNS T2-focal lesions on cervical cord atrophy and disability in multiple sclerosis.
Mult Scler. 2019 Jul 26:1352458519865989. doi: 10.1177/1352458519865989.
PubMed Text format Abstract available

CALLESEN J, Cattaneo D, Brincks J, Kjeldgaard Jorgensen ML, et al
How do resistance training and balance and motor control training affect gait performance and fatigue impact in people with multiple sclerosis? A randomized controlled multi-center study.
Mult Scler. 2019 Jul 24:1352458519865740. doi: 10.1177/1352458519865740.
PubMed Text format Abstract available

BRIGGS FB, Hill E
Estimating the prevalence of multiple sclerosis using 56.6 million electronic health records from the United States.
Mult Scler. 2019 Jul 24:1352458519864681. doi: 10.1177/1352458519864681.
PubMed Text format Abstract available

HACOHEN Y, Brownlee W, Mankad K, Chong WK', et al
Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort.
Mult Scler. 2019 Jul 18:1352458519863781. doi: 10.1177/1352458519863781.
PubMed Text format Abstract available

CAMARA-LEMARROY CR, Silva C, Greenfield J, Liu WQ, et al
Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity.
Mult Scler. 2019 Jul 18:1352458519863133. doi: 10.1177/1352458519863133.
PubMed Text format Abstract available

June 2019

DE LOTT LB, Zerafa S, Shedden K, Dunietz GL, et al
Multiple sclerosis relapse risk in the postoperative period: Effects of invasive surgery and anesthesia.
Mult Scler. 2019 Jun 25:1352458519860304. doi: 10.1177/1352458519860304.
PubMed Text format Abstract available

INEICHEN BV, Moridi T, Granberg T, Piehl F, et al
Rituximab treatment for multiple sclerosis.
Mult Scler. 2019 Jun 25:1352458519858604. doi: 10.1177/1352458519858604.
PubMed Text format Abstract available

LEAVITT VM, Brandstadter R, Fabian M, Katz Sand I, et al
Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis.
Mult Scler. 2019 Jun 24:1352458519860319. doi: 10.1177/1352458519860319.
PubMed Text format Abstract available

PERONI S, Sorosina M, Malhotra S, Clarelli F, et al
A pharmacogenetic study implicates NINJ2 in the response to Interferon-beta in multiple sclerosis.
Mult Scler. 2019 Jun 21:1352458519851428. doi: 10.1177/1352458519851428.
PubMed Text format Abstract available

MARCK CH, das Nair R, Grech LB, Borland R, et al
Modifiable risk factors for poor health outcomes in multiple sclerosis: The urgent need for research to maximise smoking cessation success.
Mult Scler. 2019 Jun 20:1352458519858730. doi: 10.1177/1352458519858730.
PubMed Text format Abstract available

FUCHS TA, Benedict RH, Wilding G, Wojcik C, et al
Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis.
Mult Scler. 2019 Jun 20:1352458519858605. doi: 10.1177/1352458519858605.
PubMed Text format Abstract available

CHATAWAY J, Weir CJ, Fox RJ
The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials.
Mult Scler. 2019 Jun 20:1352458519856985. doi: 10.1177/1352458519856985.
PubMed Text format

CAMBRON M, Mostert J, D'Hooghe M, Nagels G, et al
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.
Mult Scler. 2019 Jun 20:1352458519843051. doi: 10.1177/1352458519843051.
PubMed Text format Abstract available

SPRENGER T, Kappos L, Radue EW, Gaetano L, et al
Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide.
Mult Scler. 2019 Jun 14:1352458519855722. doi: 10.1177/1352458519855722.
PubMed Text format Abstract available

GABR RE, Coronado I, Robinson M, Sujit SJ, et al
Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study.
Mult Scler. 2019 Jun 13:1352458519856843. doi: 10.1177/1352458519856843.
PubMed Text format Abstract available

KLINEOVA S, Brandstadter R, Fabian MT, Sand IK, et al
Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis.
Mult Scler. 2019 Jun 7:1352458519852725. doi: 10.1177/1352458519852725.
PubMed Text format Abstract available

BROWN JWL, Prados Carrasco F, Eshaghi A, Sudre CH, et al
Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab.
Mult Scler. 2019 Jun 6:1352458519852093. doi: 10.1177/1352458519852093.
PubMed Text format Abstract available

MARRIE RA, Dufault B, Tyry T, Cutter GR, et al
Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis.
Mult Scler. 2019 Jun 4:1352458519852722. doi: 10.1177/1352458519852722.
PubMed Text format Abstract available

STAMPANONI BASSI M, Iezzi E, Buttari F, Gilio L, et al
Obesity worsens central inflammation and disability in multiple sclerosis.
Mult Scler. 2019 Jun 4:1352458519853473. doi: 10.1177/1352458519853473.
PubMed Text format Abstract available

May 2019

AKGUN K, Ziemssen T
Response to Hyun J.W. et al. "Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis".
Mult Scler. 2019 May 30:1352458519854263. doi: 10.1177/1352458519854263.
PubMed Text format

PELLEGRINI F, Copetti M, Bovis F, Cheng D, et al
A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis.
Mult Scler. 2019 May 30:1352458519849513. doi: 10.1177/1352458519849513.
PubMed Text format Abstract available

ARROYO R, Bury DP, Guo JD, Margolin DH, et al
Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
Mult Scler. 2019 May 30:1352458519849796. doi: 10.1177/1352458519849796.
PubMed Text format Abstract available

MOBERG JY, Laursen B, Thygesen LC, Magyari M, et al
Reproductive history of the Danish multiple sclerosis population: A register-based study.
Mult Scler. 2019 May 30:1352458519851245. doi: 10.1177/1352458519851245.
PubMed Text format Abstract available

CAPONE F, Collorone S, Cortese R, Di Lazzaro V, et al
Fatigue in multiple sclerosis: The role of thalamus.
Mult Scler. 2019 May 29:1352458519851247. doi: 10.1177/1352458519851247.
PubMed Text format Abstract available

MCCOMBE PA
Women who contributed to past research in multiple sclerosis.
Mult Scler. 2019 May 28:1352458519846101. doi: 10.1177/1352458519846101.
PubMed Text format Abstract available

MARRIE RA
Recognizing the diversity gap in multiple sclerosis.
Mult Scler. 2019 May 28:1352458519850070. doi: 10.1177/1352458519850070.
PubMed Text format

AHRWEILLER K, Rousseau C, Le Page E, Bajeux E, et al
Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis.
Mult Scler. 2019 May 16:1352458519848090. doi: 10.1177/1352458519848090.
PubMed Text format Abstract available

MURPHY OC, Kwakyi O, Iftikhar M, Zafar S, et al
Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures.
Mult Scler. 2019 May 16:1352458519845116. doi: 10.1177/1352458519845116.
PubMed Text format Abstract available

PUGLIATTI M
Changes in the sex ratio are a good indicator of changes in multiple sclerosis incidence - Commentary.
Mult Scler. 2019 May 15:1352458519845114. doi: 10.1177/1352458519845114.
PubMed Text format

KOPP TI, Blinkenberg M, Chalmer TA, Petersen T, et al
Predictors of treatment outcome in patients with paediatric onset multiple sclerosis.
Mult Scler. 2019 May 13:1352458519846100. doi: 10.1177/1352458519846100.
PubMed Text format Abstract available

CONTE A, Gianni C, Belvisi D, Cortese A, et al
Deep grey matter involvement and altered sensory gating in multiple sclerosis.
Mult Scler. 2019 May 13:1352458519845287. doi: 10.1177/1352458519845287.
PubMed Text format Abstract available

FITZGERALD KC, Salter A, Tyry T, Fox RJ, et al
Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis.
Mult Scler. 2019 May 13:1352458519845836. doi: 10.1177/1352458519845836.
PubMed Text format Abstract available

MOSS BP, Cohen JA
The emergence of follow-on disease-modifying therapies for multiple sclerosis.
Mult Scler. 2019 May 10:1352458519845106. doi: 10.1177/1352458519845106.
PubMed Text format Abstract available

TUR C, Grussu F, Prados F, Charalambous T, et al
A multi-shell multi-tissue diffusion study of brain connectivity in early multiple sclerosis.
Mult Scler. 2019 May 10:1352458519845105. doi: 10.1177/1352458519845105.
PubMed Text format Abstract available

FALET JR, Deshmukh S, Al-Jassim A, Sigler G, et al
The neurologist's role in disabling multiple sclerosis: A qualitative study of patient and care provider perspectives.
Mult Scler. 2019 May 10:1352458519845107. doi: 10.1177/1352458519845107.
PubMed Text format Abstract available

April 2019

PHELPS R, Winston JA, Wynn D, Habek M, et al
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
Mult Scler. 2019 Apr 15:1352458519841829. doi: 10.1177/1352458519841829.
PubMed Text format Abstract available

BARLETTA VT, Herranz E, Treaba CA, Ouellette R, et al
Evidence of diffuse cerebellar neuroinflammation in multiple sclerosis by (11)C-PBR28 MR-PET.
Mult Scler. 2019 Apr 11:1352458519843048. doi: 10.1177/1352458519843048.
PubMed Text format Abstract available

VUKUSIC S, Coyle PK, Jurgensen S, Truffinet P, et al
Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.
Mult Scler. 2019 Apr 10:1352458519843055. doi: 10.1177/1352458519843055.
PubMed Text format Abstract available

BROWN JWL, Chowdhury A, Kanber B, Prados Carrasco F, et al
Magnetisation transfer ratio abnormalities in primary and secondary progressive multiple sclerosis.
Mult Scler. 2019 Apr 8:1352458519841810. doi: 10.1177/1352458519841810.
PubMed Text format Abstract available

BANWELL B
Are children with multiple sclerosis really "old" adults.
Mult Scler. 2019 Apr 4:1352458519841505. doi: 10.1177/1352458519841505.
PubMed Text format

BARTELS F, Nobis K, Cooper G, Wendel E, et al
Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure.
Mult Scler. 2019 Apr 4:1352458519829698. doi: 10.1177/1352458519829698.
PubMed Text format Abstract available

March 2019

HYUN JW, Kim Y, Kim G, Kim SH, et al
Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
Mult Scler. 2019 Mar 26:1352458519840757. doi: 10.1177/1352458519840757.
PubMed Text format Abstract available

BOONSTRA FM, Noffs G, Perera T, Jokubaitis VG, et al
Functional neuroplasticity in response to cerebello-thalamic injury underpins the clinical presentation of tremor in multiple sclerosis.
Mult Scler. 2019 Mar 25:1352458519837706. doi: 10.1177/1352458519837706.
PubMed Text format Abstract available

BAGNATO F, Franco G, Ye F, Fan R, et al
Selective inversion recovery quantitative magnetization transfer imaging: Toward a 3 T clinical application in multiple sclerosis.
Mult Scler. 2019 Mar 25:1352458519833018. doi: 10.1177/1352458519833018.
PubMed Text format Abstract available

D'AMBROSIO A, Valsasina P, Gallo A, De Stefano N, et al
Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis.
Mult Scler. 2019 Mar 19:1352458519837707. doi: 10.1177/1352458519837707.
PubMed Text format Abstract available

RUSSO CV, Sacca F, Paternoster M, Buonomo AR, et al
Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis.
Mult Scler. 2019 Mar 18:1352458518813110. doi: 10.1177/1352458518813110.
PubMed Text format

STRAUDI S, Manfredini F, Lamberti N, Martinuzzi C, et al
Robot-assisted gait training is not superior to intensive overground walking in multiple sclerosis with severe disability (the RAGTIME study): A randomized controlled trial.
Mult Scler. 2019 Mar 4:1352458519833901. doi: 10.1177/1352458519833901.
PubMed Text format Abstract available

February 2019

PALMER AJ, van der Mei I, Taylor BV, Clarke PM, et al
Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia.
Mult Scler. 2019 Feb 26:1352458519831213. doi: 10.1177/1352458519831213.
PubMed Text format Abstract available

URRU SA, Antonelli A, Sechi GM
Prevalence of multiple sclerosis in Sardinia: A systematic cross-sectional multi-source survey.
Mult Scler. 2019 Feb 22:1352458519828600. doi: 10.1177/1352458519828600.
PubMed Text format Abstract available

PORTACCIO E, Amato MP
Breastfeeding and post-partum relapses in multiple sclerosis patients.
Mult Scler. 2019 Feb 22:1352458519830588. doi: 10.1177/1352458519830588.
PubMed Text format Abstract available

JAKIMOVSKI D, Ramanathan M, Weinstock-Guttman B, Bergsland N, et al
Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.
Mult Scler. 2019 Feb 13:1352458519828667. doi: 10.1177/1352458519828667.
PubMed Text format Abstract available

SOTIRCHOS ES, Gonzalez-Caldito N, Dewey BE, Fitzgerald KC, et al
Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
Mult Scler. 2019 Feb 11:1352458519826364. doi: 10.1177/1352458519826364.
PubMed Text format Abstract available

CICERO CE, Patti F, Lo Fermo S, Giuliano L, et al
Lack of association between Toxocara canis and multiple sclerosis: A population-based case-control study.
Mult Scler. 2019 Feb 11:1352458518825394. doi: 10.1177/1352458518825394.
PubMed Text format

LEFEUVRE JA, Guy JR, Luciano NJ, Ha SK, et al
The spectrum of spinal cord lesions in a primate model of multiple sclerosis.
Mult Scler. 2019 Feb 7:1352458518822408. doi: 10.1177/1352458518822408.
PubMed Text format Abstract available

NICOLETTI CG, Monteleone F, Marfia GA, Usiello A, et al
Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis.
Mult Scler. 2019 Feb 7:1352458519828294. doi: 10.1177/1352458519828294.
PubMed Text format Abstract available

RAIMO S, Spitaleri D, Trojano L, Santangelo G, et al
Apathy as a herald of cognitive changes in multiple sclerosis: A 2-year follow-up study.
Mult Scler. 2019 Feb 7:1352458519828296. doi: 10.1177/1352458519828296.
PubMed Text format Abstract available

PLANCHE V, Su JH, Mournet S, Saranathan M, et al
White-matter-nulled MPRAGE at 7T reveals thalamic lesions and atrophy of specific thalamic nuclei in multiple sclerosis.
Mult Scler. 2019 Feb 7:1352458519828297. doi: 10.1177/1352458519828297.
PubMed Text format Abstract available

CHARD DT
Commentary on Al Hussona et al. 'New-onset seizures as a sole clinical presentation of multiple sclerosis'.
Mult Scler. 2019;25:298-299.
PubMed Text format Abstract available

January 2019

STORK L, Bruck W, von Gottberg P, Pulkowski U, et al
Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis.
Mult Scler. 2019 Jan 18:1352458518819098. doi: 10.1177/1352458518819098.
PubMed Text format Abstract available

CORDANI C, Meani A, Esposito F, Valsasina P, et al
Imaging correlates of hand motor performance in multiple sclerosis: A multiparametric structural and functional MRI study.
Mult Scler. 2019 Jan 18:1352458518822145. doi: 10.1177/1352458518822145.
PubMed Text format Abstract available

VALENCIA-SANCHEZ C, Goodman BP, Carter JL, Wingerchuk DM, et al
The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations.
Mult Scler. 2019 Jan 18:1352458518823482. doi: 10.1177/1352458518823482.
PubMed Text format Abstract available

VAN MUNSTER CE, Kaya L, Obura M, Kalkers NF, et al
Minimal clinically important difference of improvement on the Arm Function in Multiple Sclerosis Questionnaire (AMSQ).
Mult Scler. 2019 Jan 18:1352458518823489. doi: 10.1177/1352458518823489.
PubMed Text format Abstract available

BARIN L, Kamm CP, Salmen A, Dressel H, et al
How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.
Mult Scler. 2019 Jan 18:1352458518823955. doi: 10.1177/1352458518823955.
PubMed Text format Abstract available

MARRODAN M, Alessandro L, Farez MF, Correale J, et al
The role of infections in multiple sclerosis.
Mult Scler. 2019 Jan 14:1352458518823940. doi: 10.1177/1352458518823940.
PubMed Text format Abstract available

PAGANI E, Rocca MA, De Meo E, Horsfield MA, et al
Structural connectivity in multiple sclerosis and modeling of disconnection.
Mult Scler. 2019 Jan 9:1352458518820759. doi: 10.1177/1352458518820759.
PubMed Text format Abstract available

JAKIMOVSKI D, Benedict RH, Marr K, Gandhi S, et al
Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients.
Mult Scler. 2019 Jan 9:1352458518819608. doi: 10.1177/1352458518819608.
PubMed Text format Abstract available

FUCHS TA, Wojcik C, Wilding GE, Pol J, et al
Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis.
Mult Scler. 2019 Jan 7:1352458518820272. doi: 10.1177/1352458518820272.
PubMed Text format Abstract available

December 2018

HOGEL H, Rissanen E, Barro C, Matilainen M, et al
Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
Mult Scler. 2018 Dec 20:1352458518819380. doi: 10.1177/1352458518819380.
PubMed Text format Abstract available

SATCHIDANAND N, Drake A, Smerbeck A, Hojnacki D, et al
Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
Mult Scler. 2018 Dec 19:1352458518815795. doi: 10.1177/1352458518815795.
PubMed Text format Abstract available

ELLIOTT C, Wolinsky JS, Hauser SL, Kappos L, et al
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
Mult Scler. 2018 Dec 19:1352458518814117. doi: 10.1177/1352458518814117.
PubMed Text format Abstract available

MATTHEWS L
Clinical commentary on 'Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases'.
Mult Scler. 2018 Dec 17:1352458518816621. doi: 10.1177/1352458518816621.
PubMed Text format

PATEL KR, Karaa A, Mateen FJ
Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases.
Mult Scler. 2018 Dec 17:1352458518800794. doi: 10.1177/1352458518800794.
PubMed Text format Abstract available

POURCHER V, Todesco E, Dubois C, Pallier C, et al
False hepatitis B and C viral serologies in patients with multiple sclerosis receiving high-dose biotin.
Mult Scler. 2018 Dec 11:1352458518818294. doi: 10.1177/1352458518818294.
PubMed Text format

BSTEH G, Algrang L, Hegen H, Auer M, et al
Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
Mult Scler. 2018 Dec 3:1352458518816614. doi: 10.1177/1352458518816614.
PubMed Text format Abstract available

VAUGHN CB, Kavak KS, Dwyer MG, Bushra A, et al
Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.
Mult Scler. 2018 Dec 3:1352458518816619. doi: 10.1177/1352458518816619.
PubMed Text format Abstract available

November 2018

BSTEH G, Berek K, Hegen H, Teuchner B, et al
Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration.
Mult Scler. 2018 Nov 22:1352458518814113. doi: 10.1177/1352458518814113.
PubMed Text format Abstract available

WOJCIK CM, Rao SM, Schembri AJ, Drake AS, et al
Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis.
Mult Scler. 2018 Nov 22:1352458518813287. doi: 10.1177/1352458518813287.
PubMed Text format Abstract available

WALLECZEK NK, Frommlet F, Bsteh G, Eggers C, et al
Month-of-birth-effect in multiple sclerosis in Austria.
Mult Scler. 2018 Nov 22:1352458518810924. doi: 10.1177/1352458518810924.
PubMed Text format Abstract available

SEGAL BM
Enhancing natural killer cells is beneficial in multiple sclerosis - Commentary.
Mult Scler. 2018 Nov 13:1352458518809296. doi: 10.1177/1352458518809296.
PubMed Text format

LIU Q, Shi FD
Enhancing natural killer cells is beneficial in multiple sclerosis - No.
Mult Scler. 2018 Nov 13:1352458518799591. doi: 10.1177/1352458518799591.
PubMed Text format

LARONI A
Enhancing natural killer cells is beneficial in multiple sclerosis - Yes.
Mult Scler. 2018 Nov 13:1352458518800776. doi: 10.1177/1352458518800776.
PubMed Text format

RAATS J, Lamers I, Baert I, Willekens B, et al
Cognitive-motor interference in persons with multiple sclerosis during five upper limb motor tasks with different complexity.
Mult Scler. 2018 Nov 12:1352458518808194. doi: 10.1177/1352458518808194.
PubMed Text format Abstract available

FOX EJ, Markowitz C, Applebee A, Montalban X, et al
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
Mult Scler. 2018 Nov 12:1352458518808189. doi: 10.1177/1352458518808189.
PubMed Text format Abstract available

LUIJTEN MA, Eekhout I, D'Hooghe M, Uitdehaag BM, et al
Development of the Arm Function in Multiple Sclerosis Questionnaire-Short Form (AMSQ-SF): A static 10-item version.
Mult Scler. 2018 Nov 9:1352458518808197. doi: 10.1177/1352458518808197.
PubMed Text format Abstract available

LAMERS I, Feys P
Patient reported outcome measures of upper limb function in multiple sclerosis: A critical overview.
Mult Scler. 2018 Nov 9:1352458518809294. doi: 10.1177/1352458518809294.
PubMed Text format

HYUN JW, Kim Y, Kim G, Kim SH, et al
Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
Mult Scler. 2018 Nov 7:1352458518810261. doi: 10.1177/1352458518810261.
PubMed Text format Abstract available

ACHIRON A, Sarova-Pinhas I, Magalashvili D, Stern Y, et al
Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy.
Mult Scler. 2018 Nov 1:1352458518809903. doi: 10.1177/1352458518809903.
PubMed Text format Abstract available

HOBART J, Bowen A, Pepper G, Crofts H, et al
International consensus on quality standards for brain health-focused care in multiple sclerosis.
Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326.
PubMed Text format Abstract available

HEALY BC, Zurawski J, Gonzalez CT, Chitnis T, et al
Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis.
Mult Scler. 2018 Nov 1:1352458518810159. doi: 10.1177/1352458518810159.
PubMed Text format Abstract available

PEETERS LM, van Munster CE, Van Wijmeersch B, Bruyndonckx R, et al
Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done!
Mult Scler. 2018 Nov 1:1352458518807076. doi: 10.1177/1352458518807076.
PubMed Text format Abstract available

October 2018

FARRELL R
Clinical commentary on "De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine".
Mult Scler. 2018 Oct 30:1352458518810661. doi: 10.1177/1352458518810661.
PubMed Text format

PANICUCCI E, Cohen M, Bourg V, Rocher F, et al
De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine.
Mult Scler. 2018 Oct 30:1352458518790379. doi: 10.1177/1352458518790379.
PubMed Text format Abstract available

DOBSON R
Clinical commentary on 'Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: a note of caution'.
Mult Scler. 2018 Oct 25:1352458518807053. doi: 10.1177/1352458518807053.
PubMed Text format

FEIGE J, Salmhofer H, Hecker C, Kunz AB, et al
Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: A note of caution.
Mult Scler. 2018 Oct 25:1352458518807059. doi: 10.1177/1352458518807059.
PubMed Text format Abstract available

AHMAD H, van der Mei I, Taylor BV, Lucas RM, et al
Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis.
Mult Scler. 2018 Oct 23:1352458518806103. doi: 10.1177/1352458518806103.
PubMed Text format Abstract available

SOELBERG SORENSEN P, Giovannoni G, Montalban X, Thalheim C, et al
The Multiple Sclerosis Care Unit.
Mult Scler. 2018 Oct 23:1352458518807082. doi: 10.1177/1352458518807082.
PubMed Text format Abstract available

ROTSTEIN DL, Cortese M, Fung TT, Chitnis T, et al
Diet quality and risk of multiple sclerosis in two cohorts of US women.
Mult Scler. 2018 Oct 23:1352458518807061. doi: 10.1177/1352458518807061.
PubMed Text format Abstract available

STROBER L, DeLuca J, Benedict RH, Jacobs A, et al
Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.
Mult Scler. 2018 Oct 18:1352458518808204. doi: 10.1177/1352458518808204.
PubMed Text format Abstract available

BURROWS DJ, McGown A, Jain SA, De Felice M, et al
Animal models of multiple sclerosis: From rodents to zebrafish.
Mult Scler. 2018 Oct 15:1352458518805246. doi: 10.1177/1352458518805246.
PubMed Text format Abstract available

DUBUISSON N, Marta M, Gnanapavan S, Turner B, et al
Inclusion criteria used in trials of people with progressive multiple sclerosis.
Mult Scler. 2018 Oct 15:1352458518803769. doi: 10.1177/1352458518803769.
PubMed Text format

GRAF J, Ringelstein M, Lepka K, Schaller J, et al
Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
Mult Scler. 2018 Oct 11:1352458518771276. doi: 10.1177/1352458518771276.
PubMed Text format Abstract available

WILLIS MD, Hope-Gill B, Flood-Page P, Joseph F, et al
Sarcoidosis following alemtuzumab treatment for multiple sclerosis.
Mult Scler. 2018 Oct 11:1352458518790391. doi: 10.1177/1352458518790391.
PubMed Text format Abstract available

CONWAY BL, Zeydan B, Uygunoglu U, Novotna M, et al
Age is a critical determinant in recovery from multiple sclerosis relapses.
Mult Scler. 2018 Oct 10:1352458518800815. doi: 10.1177/1352458518800815.
PubMed Text format Abstract available

KALB R, Beier M, Benedict RH, Charvet L, et al
Recommendations for cognitive screening and management in multiple sclerosis care.
Mult Scler. 2018 Oct 10:1352458518803785. doi: 10.1177/1352458518803785.
PubMed Text format Abstract available

VILARINO-GUELL C, Encarnacion M, Bernales CQ, Sadovnick AD, et al
Analysis of Canadian multiple sclerosis patients does not support a role for FKBP6 in disease.
Mult Scler. 2018 Oct 9:1352458518803789. doi: 10.1177/1352458518803789.
PubMed Text format

KREMER D, Akkermann R, Kury P, Dutta R, et al
Current advancements in promoting remyelination in multiple sclerosis.
Mult Scler. 2018 Oct 1:1352458518800827. doi: 10.1177/1352458518800827.
PubMed Text format Abstract available

TATEO F, Grassivaro F, Ermani M, Puthenparampil M, et al
PM2.5 levels strongly associate with multiple sclerosis prevalence in the Province of Padua, Veneto Region, North-East Italy.
Mult Scler. 2018 Oct 1:1352458518803273. doi: 10.1177/1352458518803273.
PubMed Text format Abstract available

September 2018

BOSE G, Atkins HL, Bowman M, Freedman MS, et al
Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis.
Mult Scler. 2018 Sep 25:1352458518802544. doi: 10.1177/1352458518802544.
PubMed Text format Abstract available

MIN M, Spelman T, Lugaresi A, Boz C, et al
Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.
Mult Scler. 2018 Sep 20:1352458518798147. doi: 10.1177/1352458518798147.
PubMed Text format Abstract available

LAVORGNA L, Brigo F, Moccia M, Leocani L, et al
e-Health and multiple sclerosis: An update.
Mult Scler. 2018 Sep 19:1352458518799629. doi: 10.1177/1352458518799629.
PubMed Text format Abstract available

ANTONAZZO IC, Poluzzi E, Forcesi E, Riise T, et al
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System.
Mult Scler. 2018 Sep 19:1352458518799598. doi: 10.1177/1352458518799598.
PubMed Text format Abstract available

ROMMER PS, Eichstadt K, Ellenberger D, Flachenecker P, et al
Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry.
Mult Scler. 2018 Sep 19:1352458518799580. doi: 10.1177/1352458518799580.
PubMed Text format Abstract available

O'GRADY KP, Dula AN, Lyttle BD, Thompson LM, et al
Glutamate-sensitive imaging and evaluation of cognitive impairment in multiple sclerosis.
Mult Scler. 2018 Sep 19:1352458518799583. doi: 10.1177/1352458518799583.
PubMed Text format Abstract available

August 2018

VAN ROSSUM JA, Killestein J, Villar LM, Riskind PN, et al
gMS-Classifier1 does not predict disability progression in multiple sclerosis.
Mult Scler. 2018 Aug 31:1352458518798048. doi: 10.1177/1352458518798048.
PubMed Text format

VAN MUNSTER CE, D'Souza M, Steinheimer S, Kamm CP, et al
Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.
Mult Scler. 2018 Aug 31:1352458518796690. doi: 10.1177/1352458518796690.
PubMed Text format Abstract available

O'MAHONY J, Marrie RA, Laporte A, Bar-Or A, et al
Pediatric-onset multiple sclerosis is associated with reduced parental health-related quality of life and family functioning.
Mult Scler. 2018 Aug 30:1352458518796676. doi: 10.1177/1352458518796676.
PubMed Text format Abstract available

BOVE R, Bevan C, Crabtree E, Zhao C, et al
Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.
Mult Scler. 2018 Aug 24:1352458518793527. doi: 10.1177/1352458518793527.
PubMed Text format Abstract available

NICHOLAS RS, Han E, Raffel J, Chataway J, et al
Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials.
Mult Scler. 2018 Aug 24:1352458518794063. doi: 10.1177/1352458518794063.
PubMed Text format Abstract available

SKJERBAEK AG, Boesen F, Petersen T, Rasmussen PV, et al
Can we trust self-reported walking distance when determining EDSS scores in patients with multiple sclerosis? The Danish MS hospitals rehabilitation study.
Mult Scler. 2018 Aug 20:1352458518795416. doi: 10.1177/1352458518795416.
PubMed Text format Abstract available

ANDERSEN C, Sondergaard HB, Bang Oturai D, Laursen JH, et al
Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort.
Mult Scler. 2018 Aug 20:1352458518795418. doi: 10.1177/1352458518795418.
PubMed Text format Abstract available

GAUZZI MC
Vitamin D-binding protein and multiple sclerosis: Evidence, controversies, and needs.
Mult Scler. 2018 Aug 16:1352458518792433. doi: 10.1177/1352458518792433.
PubMed Text format Abstract available

SELLEBJERG F, Royen L, Soelberg Sorensen P, Oturai AB, et al
Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
Mult Scler. 2018 Aug 16:1352458518794308. doi: 10.1177/1352458518794308.
PubMed Text format Abstract available

VISWANATHAN S, Wah LM
A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia.
Mult Scler. 2018 Aug 16:1352458518792430. doi: 10.1177/1352458518792430.
PubMed Text format Abstract available

SEEBACHER B, Kuisma R, Glynn A, Berger T, et al
Effects and mechanisms of differently cued and non-cued motor imagery in people with multiple sclerosis: A randomised controlled trial.
Mult Scler. 2018 Aug 14:1352458518795332. doi: 10.1177/1352458518795332.
PubMed Text format Abstract available

PIETROBONI AM, Caprioli M, Carandini T, Scarioni M, et al
CSF beta-amyloid predicts prognosis in patients with multiple sclerosis.
Mult Scler. 2018 Aug 7:1352458518791709. doi: 10.1177/1352458518791709.
PubMed Text format Abstract available

ROCCA MA, Meani A, Fumagalli S, Pagani E, et al
Functional and structural plasticity following action observation training in multiple sclerosis.
Mult Scler. 2018 Aug 7:1352458518792771. doi: 10.1177/1352458518792771.
PubMed Text format Abstract available

KUSPINAR A, Mayo NE
Validation of the preference-based multiple sclerosis index.
Mult Scler. 2018 Aug 2:1352458518792423. doi: 10.1177/1352458518792423.
PubMed Text format Abstract available

TOMASSINI V, Fanelli F, Prosperini L, Cerqua R, et al
Predicting the profile of increasing disability in multiple sclerosis.
Mult Scler. 2018 Aug 2:1352458518790397. doi: 10.1177/1352458518790397.
PubMed Text format Abstract available

PETERSEN ER, Sondergaard HB, Laursen JH, Olsson AG, et al
Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.
Mult Scler. 2018 Aug 2:1352458518791753. doi: 10.1177/1352458518791753.
PubMed Text format Abstract available

DI STADIO A, Ralli M
Inner ear involvement in multiple sclerosis: An underestimated condition?
Mult Scler. 2018;24:1264-1265.
PubMed Text format

BHAN A, Jacobsen C, Myhr KM, Dalen I, et al
Neurofilaments and 10-year follow-up in multiple sclerosis.
Mult Scler. 2018 Aug 1:1352458518782005. doi: 10.1177/1352458518782005.
PubMed Text format Abstract available

July 2018

YANG R, Dunn JF
Multiple sclerosis disease progression: Contributions from a hypoxia-inflammation cycle.
Mult Scler. 2018 Jul 27:1352458518791683. doi: 10.1177/1352458518791683.
PubMed Text format Abstract available

SACCA F, Lanzillo R, Signori A, Maniscalco GT, et al
Determinants of therapy switch in multiple sclerosis treatment-naive patients: A real-life study.
Mult Scler. 2018 Jul 25:1352458518790390. doi: 10.1177/1352458518790390.
PubMed Text format Abstract available

HYUN JW, Kim W, Huh SY, Park MS, et al
Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
Mult Scler. 2018 Jul 25:1352458518790702. doi: 10.1177/1352458518790702.
PubMed Text format Abstract available

HOLM HANSEN R, Hojsgaard Chow H, Sellebjerg F, Rode von Essen M, et al
Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis.
Mult Scler. 2018 Jul 25:1352458518790417. doi: 10.1177/1352458518790417.
PubMed Text format Abstract available

COHEN JA, Comi G, Arnold DL, Bar-Or A, et al
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884.
PubMed Text format Abstract available

LIN F, Zivadinov R, Hagemeier J, Weinstock-Guttman B, et al
Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition.
Mult Scler. 2018 Jul 1:1352458518788218. doi: 10.1177/1352458518788218.
PubMed Text format Abstract available

SENDERS A, Hanes D, Bourdette D, Carson K, et al
Impact of mindfulness-based stress reduction for people with multiple sclerosis at 8 weeks and 12 months: A randomized clinical trial.
Mult Scler. 2018 Jul 1:1352458518786650. doi: 10.1177/1352458518786650.
PubMed Text format Abstract available

FISSOLO N, Cervera-Carles L, Villar Guimerans LM, Lleo A, et al
Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis.
Mult Scler. 2018 Jul 1:1352458518786055. doi: 10.1177/1352458518786055.
PubMed Text format Abstract available

OSHIMA Y, Tanimoto T, Yuji K, Tojo A, et al
Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Mult Scler. 2018 Jul 1:1352458518786075. doi: 10.1177/1352458518786075.
PubMed Text format Abstract available

WIJNANDS JM, Zhu F, Kingwell E, Zhao Y, et al
Five years before multiple sclerosis onset: Phenotyping the prodrome.
Mult Scler. 2018 Jul 1:1352458518783662. doi: 10.1177/1352458518783662.
PubMed Text format Abstract available

WONG YYM, van der Vuurst de Vries RM, van Pelt ED, Ketelslegers IA, et al
T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes.
Mult Scler. 2018 Jul 1:1352458518786655. doi: 10.1177/1352458518786655.
PubMed Text format Abstract available

KEARNEY H
Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - No.
Mult Scler. 2018 Jul 1:1352458518770279. doi: 10.1177/1352458518770279.
PubMed Text format

SASTRE-GARRIGA J
Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Commentary.
Mult Scler. 2018 Jul 1:1352458518783362. doi: 10.1177/1352458518783362.
PubMed Text format

CORTESE R, Ciccarelli O
Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Yes.
Mult Scler. 2018 Jul 1:1352458518778010. doi: 10.1177/1352458518778010.
PubMed Text format

June 2018

MESCHERIAKOVA JY, Verkerk AJ, Amin N, Uitterlinden AG, et al
Linkage analysis and whole exome sequencing identify a novel candidate gene in a Dutch multiple sclerosis family.
Mult Scler. 2018 Jun 1:1352458518777202. doi: 10.1177/1352458518777202.
PubMed Text format Abstract available

PUTHENPARAMPIL M, Zito A, Pantano G, Federle L, et al
Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset.
Mult Scler. 2018 Jun 1:1352458518779951. doi: 10.1177/1352458518779951.
PubMed Text format Abstract available

AL HUSSONA M, Kearney H, Fisher A, Lynch J, et al
New onset seizures as a sole clinical presentation of multiple sclerosis.
Mult Scler. 2018 Jun 1:1352458518781994. doi: 10.1177/1352458518781994.
PubMed Text format Abstract available

REDDEL SW, Barnett MH, Riminton S, Dugal T, et al
Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study.
Mult Scler. 2018 Jun 1:1352458518783673. doi: 10.1177/1352458518783673.
PubMed Text format Abstract available

CHEN J, Taylor B, Palmer AJ, Kirk-Brown A, et al
Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis.
Mult Scler. 2018 Jun 1:1352458518781971. doi: 10.1177/1352458518781971.
PubMed Text format Abstract available

MANOUCHEHRINIA A, Zhu F, Piani-Meier D, Lange M, et al
Predicting risk of secondary progression in multiple sclerosis: A nomogram.
Mult Scler. 2018 Jun 1:1352458518783667. doi: 10.1177/1352458518783667.
PubMed Text format Abstract available

GALLAGHER LG, Ilango S, Wundes A, Stobbe GA, et al
Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study.
Mult Scler. 2018 Jun 1:1352458518783343. doi: 10.1177/1352458518783343.
PubMed Text format Abstract available

MAGALHAES S, Banwell B, Bar-Or A, Fortier I, et al
A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit.
Mult Scler. 2018 Jun 1:1352458518783345. doi: 10.1177/1352458518783345.
PubMed Text format Abstract available

ALVES-LEON SV, Lima MDR, Nunes PCG, Chimelli LMC, et al
Zika virus found in brain tissue of a multiple sclerosis patient undergoing an acute disseminated encephalomyelitis-like episode.
Mult Scler. 2018 Jun 1:1352458518781992. doi: 10.1177/1352458518781992.
PubMed Text format Abstract available

May 2018

FROEHLICH A, Schmidt S, Landsberg J, Bieber T, et al
Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod.
Mult Scler. 2018 May 1:1352458518774444. doi: 10.1177/1352458518774444.
PubMed Text format

NAUTA IM, Balk LJ, Sonder JM, Hulst HE, et al
The clinical value of the patient-reported multiple sclerosis neuropsychological screening questionnaire.
Mult Scler. 2018 May 1:1352458518777295. doi: 10.1177/1352458518777295.
PubMed Text format Abstract available

ROMME CHRISTENSEN J, Komori M, von Essen MR, Ratzer R, et al
CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
Mult Scler. 2018 May 1:1352458518774880. doi: 10.1177/1352458518774880.
PubMed Text format Abstract available

MILLS EA, Mao-Draayer Y
Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.
Mult Scler. 2018 May 1:1352458518775550. doi: 10.1177/1352458518775550.
PubMed Text format Abstract available

VAN DER VUURST DE VRIES RM, Wong YYM, Mescheriakova JY, van Pelt ED, et al
High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
Mult Scler. 2018 May 1:1352458518775303. doi: 10.1177/1352458518775303.
PubMed Text format Abstract available

SCHEE JP, Viswanathan S
Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum.
Mult Scler. 2018 May 1:1352458518775912. doi: 10.1177/1352458518775912.
PubMed Text format Abstract available

BOESEN MS, Koch-Henriksen N, Thygesen LC, Eriksson F, et al
Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study.
Mult Scler. 2018 May 1:1352458518771871. doi: 10.1177/1352458518771871.
PubMed Text format Abstract available

BAKER G, Nair KPS, Baster K, Rosato R, et al
Reliability and acceptability of the Multiple Sclerosis Quality of Life-29 questionnaire in an English-speaking cohort.
Mult Scler. 2018 May 1:1352458518776583. doi: 10.1177/1352458518776583.
PubMed Text format Abstract available

BEESLEY R, Anderson V, Harding KE, Joseph F, et al
Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis.
Mult Scler. 2018 May 1:1352458518778007. doi: 10.1177/1352458518778007.
PubMed Text format

HUGOS CL, Cameron MH, Chen Z, Chen Y, et al
A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Long-term (12-month) follow-up at one site.
Mult Scler. 2018 May 1:1352458518775920. doi: 10.1177/1352458518775920.
PubMed Text format Abstract available

TSAGKAS C, Magon S, Gaetano L, Pezold S, et al
Preferential spinal cord volume loss in primary progressive multiple sclerosis.
Mult Scler. 2018 May 1:1352458518775006. doi: 10.1177/1352458518775006.
PubMed Text format Abstract available

MARANZANO J, Till C, Assemlal HE, Fonov V, et al
Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI.
Mult Scler. 2018 May 1:1352458518779952. doi: 10.1177/1352458518779952.
PubMed Text format Abstract available

BJORNEVIK K, Myhr KM, Beiske A, Bjerve KS, et al
alpha-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.
Mult Scler. 2018 May 1:1352458518779925. doi: 10.1177/1352458518779925.
PubMed Text format Abstract available

April 2018

ALMEIDA KJ, Barreto-Soares RV, Campos-Sousa RN, Campos-Sousa MG, et al
Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518763091. doi: 10.1177/1352458518763091.
PubMed Text format Abstract available

MCNICHOLAS N, Lockhart A, Yap SM, O'Connell K, et al
New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518770088. doi: 10.1177/1352458518770088.
PubMed Text format Abstract available

KREMER D, Kury P, Hartung HP
ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518768770. doi: 10.1177/1352458518768770.
PubMed Text format Abstract available

KOBELT G, Langdon D, Jonsson L
The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: The case of multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518769837. doi: 10.1177/1352458518769837.
PubMed Text format Abstract available

VAVASOUR IM, Tam R, Li DK, Laule C, et al
A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.
Mult Scler. 2018 Apr 1:1352458518770085. doi: 10.1177/1352458518770085.
PubMed Text format Abstract available

MARRIE RA, Montalban X
Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.
Mult Scler. 2018;24:558-562.
PubMed Text format

LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518768433. doi: 10.1177/1352458518768433.
PubMed Text format Abstract available

SAUL A, Taylor B, Simpson S Jr, Ponsonby AL, et al
Polymorphism in the serotonin transporter gene polymorphisms ( 5-HTTLPR) modifies the association between significant life events and depression in people with multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518770021. doi: 10.1177/1352458518770021.
PubMed Text format Abstract available

LLUFRIU S, Rocca MA, Pagani E, Riccitelli GC, et al
Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis.
Mult Scler. 2018 Apr 1:1352458518771838. doi: 10.1177/1352458518771838.
PubMed Text format Abstract available

CREARY LE, Mallempati KC, Gangavarapu S, Caillier SJ, et al
Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518770019. doi: 10.1177/1352458518770019.
PubMed Text format Abstract available

MCCLURG D, Bugge C, Elders A, Irshad T, et al
Factors affecting continuation of clean intermittent catheterisation in people with multiple sclerosis: Results of the COSMOS mixed-methods study.
Mult Scler. 2018 Apr 1:1352458518768722. doi: 10.1177/1352458518768722.
PubMed Text format Abstract available

WAGLEY S, Bokori-Brown M, Morcrette H, Malaspina A, et al
Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518767327. doi: 10.1177/1352458518767327.
PubMed Text format Abstract available

GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan KW, et al
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Mult Scler. 2018 Apr 1:1352458518771875. doi: 10.1177/1352458518771875.
PubMed Text format Abstract available

GIORDANA MT, Cavalla P, Uccelli A, Laroni A, et al
Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.
Mult Scler. 2018 Apr 1:1352458518763095. doi: 10.1177/1352458518763095.
PubMed Text format Abstract available

GIACOMINI PS
Rebound disease in multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518772913. doi: 10.1177/1352458518772913.
PubMed Text format

HARMEL P, Schlunk F, Harms L
Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
Mult Scler. 2018 Apr 1:1352458517741191. doi: 10.1177/1352458517741191.
PubMed Text format Abstract available

March 2018

KOENIG KA, Rao SM, Lowe MJ, Lin J, et al
The role of the thalamus and hippocampus in episodic memory performance in patients with multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518760716. doi: 10.1177/1352458518760716.
PubMed Text format Abstract available

GOBEL K, Ruck T, Meuth SG
Cytokine signaling in multiple sclerosis: Lost in translation.
Mult Scler. 2018 Mar 1:1352458518763094. doi: 10.1177/1352458518763094.
PubMed Text format Abstract available

LEE JY, De Jager PL
What is the epigenome and is it involved in multiple sclerosis?
Mult Scler. 2018;24:268-269.
PubMed Text format

SILLER N, Kuhle J, Muthuraman M, Barro C, et al
Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518765666. doi: 10.1177/1352458518765666.
PubMed Text format Abstract available

SOWA P, Harbo HF, White NS, Celius EG, et al
Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518765671. doi: 10.1177/1352458518765671.
PubMed Text format Abstract available

CORTI L, Ayrignac X, Carra Dalliere C, Charif M, et al
Late activity rebound in non-active multiple sclerosis: A rare event.
Mult Scler. 2018 Mar 1:1352458518765670. doi: 10.1177/1352458518765670.
PubMed Text format

CASTELLI L, Prosperini L, Pozzilli C
Balance worsening associated with nabiximols in multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518765649. doi: 10.1177/1352458518765649.
PubMed Text format Abstract available

GRAETZ C, Groger A, Luessi F, Salmen A, et al
Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541.
PubMed Text format Abstract available

HUA LH, Fan TH, Conway D, Thompson N, et al
Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
Mult Scler. 2018 Mar 1:1352458518765656. doi: 10.1177/1352458518765656.
PubMed Text format Abstract available

LANZILLO R, Moccia M, Criscuolo C, Cennamo G, et al
Optical coherence tomography angiography detects retinal vascular alterations in different phases of multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518768060. doi: 10.1177/1352458518768060.
PubMed Text format

VAN GEEST Q, Boeschoten RE, Keijzer MJ, Steenwijk MD, et al
Fronto-limbic disconnection in patients with multiple sclerosis and depression.
Mult Scler. 2018 Mar 1:1352458518767051. doi: 10.1177/1352458518767051.
PubMed Text format Abstract available

TOLEDANO M, Weinshenker BG, Kaufmann TJ, Parisi JE, et al
Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518767045. doi: 10.1177/1352458518767045.
PubMed Text format Abstract available

LEIBOVITCH EC, Lin CM, Billioux BJ, Graves J, et al
Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls.
Mult Scler. 2018 Mar 1:1352458518765654. doi: 10.1177/1352458518765654.
PubMed Text format Abstract available

February 2018

JAEGER S, Paul F, Scheel M, Brandt A, et al
Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex.
Mult Scler. 2018 Feb 1:1352458518758911. doi: 10.1177/1352458518758911.
PubMed Text format Abstract available

DE STEFANO N, Giorgio A, Tintore M, Pia Amato M, et al
Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations.
Mult Scler. 2018;24:214-221.
PubMed Text format

ROOSTAEI T, Sadaghiani S, Mashhadi R, Falahatian M, et al
Convergent effects of a functional C3 variant on brain atrophy, demyelination, and cognitive impairment in multiple sclerosis.
Mult Scler. 2018 Feb 1:1352458518760715. doi: 10.1177/1352458518760715.
PubMed Text format Abstract available

CAVALERA C, Rovaris M, Mendozzi L, Pugnetti L, et al
Online meditation training for people with multiple sclerosis: A randomized controlled trial.
Mult Scler. 2018 Feb 1:1352458518761187. doi: 10.1177/1352458518761187.
PubMed Text format Abstract available

CAMARA-LEMARROY CR, Castillo J, Sastre-Garriga J, Tintore M, et al
Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.
Mult Scler. 2018 Feb 1:1352458518761185. doi: 10.1177/1352458518761185.
PubMed Text format Abstract available

PIEHL F, Hillert J
Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.
Mult Scler. 2018 Feb 1:1352458518757930. doi: 10.1177/1352458518757930.
PubMed Text format

CREE BA
Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary.
Mult Scler. 2018 Feb 1:1352458518760717. doi: 10.1177/1352458518760717.
PubMed Text format

WALLIN MT
Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No.
Mult Scler. 2018 Feb 1:1352458518757931. doi: 10.1177/1352458518757931.
PubMed Text format

BARKHOF F
The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - Commentary.
Mult Scler. 2018;24:125-126.
PubMed Text format

PORTER B
Commentary on "Localized pigmentation disorder after subcutaneous pegylated interferon beta 1a injection" by Coghe et al.
Mult Scler. 2018;24:233-235.
PubMed Text format

January 2018

HILVEN K, Vandebergh M, Smets I, Mallants K, et al
Genetic basis for relapse rate in multiple sclerosis: Association with LRP2 genetic variation.
Mult Scler. 2018 Jan 1:1352458517749894. doi: 10.1177/1352458517749894.
PubMed Text format Abstract available

FEUCHT N, Maier M, Lepennetier G, Pettenkofer M, et al
Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517750009. doi: 10.1177/1352458517750009.
PubMed Text format Abstract available

DI STADIO A, Ralli M
Inner ear involvement in multiple sclerosis: An underestimated condition?
Mult Scler. 2018 Jan 1:1352458518750010. doi: 10.1177/1352458518750010.
PubMed Text format

DAMOTTE V, Lizee A, Tremblay M, Agrawal A, et al
Harnessing electronic medical records to advance research on multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517747407. doi: 10.1177/1352458517747407.
PubMed Text format Abstract available

DE STEFANO N, Giorgio A
Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al.
Mult Scler. 2018 Jan 1:1352458517748476. doi: 10.1177/1352458517748476.
PubMed Text format

SCHIFFMANN I, Scheiderbauer J, Riemann-Lorenz K, Heesen C, et al
Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?
Mult Scler. 2018 Jan 1:1352458517749895. doi: 10.1177/1352458517749895.
PubMed Text format

SEGAL BM, Cohen JA, Antel J
Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2017: Environmental factors, genetics, and epigenetics in MS susceptibility and clinical course.
Mult Scler. 2018;24:4-5.
PubMed Text format Abstract available

TREMLETT H, Waubant E
Gut microbiome and pediatric multiple sclerosis.
Mult Scler. 2018;24:64-68.
PubMed Text format Abstract available

CASTRO K, Casaccia P
Epigenetic modifications in brain and immune cells of multiple sclerosis patients.
Mult Scler. 2018;24:69-74.
PubMed Text format Abstract available

TANKOU SK, Regev K, Healy BC, Cox LM, et al
Investigation of probiotics in multiple sclerosis.
Mult Scler. 2018;24:58-63.
PubMed Text format Abstract available

VOSKUHL RR, Sawalha AH, Itoh Y
Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression.
Mult Scler. 2018;24:22-31.
PubMed Text format Abstract available

HAASE S, Haghikia A, Gold R, Linker RA, et al
Dietary fatty acids and susceptibility to multiple sclerosis.
Mult Scler. 2018;24:12-16.
PubMed Text format Abstract available

HARROUD A, Richards JB
Mendelian randomization in multiple sclerosis: A causal role for vitamin D and obesity?
Mult Scler. 2018;24:80-85.
PubMed Text format Abstract available

DOLEI A
The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis.
Mult Scler. 2018;24:42-47.
PubMed Text format Abstract available

CANTO E, Oksenberg JR
Multiple sclerosis genetics.
Mult Scler. 2018;24:75-79.
PubMed Text format Abstract available

WAUBANT E
Effect of puberty on multiple sclerosis risk and course.
Mult Scler. 2018;24:32-35.
PubMed Text format Abstract available

HODEL J, Bapst B, Outteryck O, Verclytte S, et al
Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
Mult Scler. 2018 Jan 1:1352458517750765. doi: 10.1177/1352458517750765.
PubMed Text format Abstract available

BOVE R, Healy BC, Musallam A, Soltany P, et al
Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.
Mult Scler. 2018 Jan 1:1352458517750768. doi: 10.1177/1352458517750768.
PubMed Text format Abstract available

RIMKUS CM, Schoonheim MM, Steenwijk MD, Vrenken H, et al
Gray matter networks and cognitive impairment in multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517751650. doi: 10.1177/1352458517751650.
PubMed Text format Abstract available

COHEN JA, Hunter SF, Brown TR, Gudesblatt M, et al
Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
Mult Scler. 2018 Jan 1:1352458518754716. doi: 10.1177/1352458518754716.
PubMed Text format Abstract available

FORD HL, Wicks CR, Stroud A, Tennant A, et al
Psychological determinants of job retention in multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458518754362. doi: 10.1177/1352458518754362.
PubMed Text format Abstract available

ROY S, Drake A, Fuchs T, Dwyer MG, et al
Longitudinal personality change associated with cognitive decline in multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517753720. doi: 10.1177/1352458517753720.
PubMed Text format Abstract available

HAUPTS MR, Spill-Askeridis P, Humpert M, Seidel D, et al
Acute exacerbations after decades of non-active chronic multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458518754365. doi: 10.1177/1352458518754365.
PubMed Text format

DI IOIA M, Farina D, di Tommaso V, Travaglini D, et al
Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517743093. doi: 10.1177/1352458517743093.
PubMed Text format Abstract available

MEUNIER B, Rico A, Seguier J, Boutiere C, et al
Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Mult Scler. 2018 Jan 1:1352458517729766. doi: 10.1177/1352458517729766.
PubMed Text format Abstract available

MONTALBAN X, Gold R, Thompson AJ, Otero-Romero S, et al
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517751049. doi: 10.1177/1352458517751049.
PubMed Text format Abstract available

LAVERY AM, Collins BN, Waldman AT, Hart CN, et al
The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk.
Mult Scler. 2018 Jan 1:1352458518757089. doi: 10.1177/1352458518757089.
PubMed Text format Abstract available

December 2017

KROTH J, Ciolac D, Fleischer V, Koirala N, et al
Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Dec 1:1352458517748474. doi: 10.1177/1352458517748474.
PubMed Text format Abstract available

HUGOS CL, Chen Z, Chen Y, Turner AP, et al
A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Short- and medium-term benefits.
Mult Scler. 2017 Dec 1:1352458517745723. doi: 10.1177/1352458517745723.
PubMed Text format Abstract available

CALLESEN J, Richter C, Kristensen C, Sunesen I, et al
Test-retest agreement and reliability of the Six Spot Step Test in persons with multiple sclerosis.
Mult Scler. 2017 Dec 1:1352458517745725. doi: 10.1177/1352458517745725.
PubMed Text format Abstract available

PEETERS LM
Fair data for next-generation management of multiple sclerosis.
Mult Scler. 2017 Dec 1:1352458517748475. doi: 10.1177/1352458517748475.
PubMed Text format Abstract available

November 2017

GRAN-RUAZ S, Mani A, O'Quinn S
An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517739976. doi: 10.1177/1352458517739976.
PubMed Text format Abstract available

MANCARDI G, Sormani MP, Muraro PA, Boffa G, et al
Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517742532. doi: 10.1177/1352458517742532.
PubMed Text format Abstract available

PIETROBONI AM, Dell'Arti L, Caprioli M, Scarioni M, et al
The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients.
Mult Scler. 2017 Nov 1:1352458517740214. doi: 10.1177/1352458517740214.
PubMed Text format Abstract available

MALHOTRA S, Sorosina M, Rio J, Peroni S, et al
NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.
Mult Scler. 2017 Nov 1:1352458517739137. doi: 10.1177/1352458517739137.
PubMed Text format Abstract available

MALINOVA TS, Dijkstra CD, de Vries HE
Serotonin: A mediator of the gut-brain axis in multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517739975. doi: 10.1177/1352458517739975.
PubMed Text format Abstract available

ABBOUD H, Hill E, Siddiqui J, Serra A, et al
Neuromodulation in multiple sclerosis.
Mult Scler. 2017;23:1663-1676.
PubMed Text format Abstract available

FEYS P, Moumdjian L, Van Halewyck F, Wens I, et al
Effects of an individual 12-week community-located "start-to-run" program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517740211. doi: 10.1177/1352458517740211.
PubMed Text format Abstract available

LOREFICE L, Fenu G, Sardu C, Frau J, et al
Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy.
Mult Scler. 2017 Nov 1:1352458517739989. doi: 10.1177/1352458517739989.
PubMed Text format Abstract available

WINGES KM, Murchison CF, Bourdette DN, Spain RI, et al
Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.
Mult Scler. 2017 Nov 1:1352458517739136. doi: 10.1177/1352458517739136.
PubMed Text format Abstract available

UHER T, Vaneckova M, Krasensky J, Sobisek L, et al
Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517742739. doi: 10.1177/1352458517742739.
PubMed Text format Abstract available

KAVALIUNAS A, Danylaite Karrenbauer V, Gyllensten H, Manouchehrinia A, et al
Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability.
Mult Scler. 2017 Nov 1:1352458517740212. doi: 10.1177/1352458517740212.
PubMed Text format Abstract available

AGIUS MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, et al
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
Mult Scler. 2017 Nov 1:1352458517740641. doi: 10.1177/1352458517740641.
PubMed Text format Abstract available

SPITERI S, Hassa T, Claros-Salinas D, Dettmers C, et al
Neural correlates of effort-dependent and effort-independent cognitive fatigue components in patients with multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517743090. doi: 10.1177/1352458517743090.
PubMed Text format Abstract available

RICCITELLI GC, Pagani E, Rodegher M, Colombo B, et al
Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517743091. doi: 10.1177/1352458517743091.
PubMed Text format Abstract available

October 2017

MOSS-MORRIS R, Norton S
Aerobic exercise, cognitive behavioural therapy and energy conservation management for multiple sclerosis (MS) fatigue: Are three trials better than one?
Mult Scler. 2017;23:1436-1440.
PubMed Text format

ZETTERBERG H, Teunissen C
Fluid biomarkers for disease activity in multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517736151. doi: 10.1177/1352458517736151.
PubMed Text format

GIANFRANCESCO MA, Stridh P, Shao X, Rhead B, et al
Genetic risk factors for pediatric-onset multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517733551. doi: 10.1177/1352458517733551.
PubMed Text format Abstract available

FOX RJ, Chataway J
Advancing trial design in progressive multiple sclerosis.
Mult Scler. 2017;23:1573-1578.
PubMed Text format Abstract available

MILLER DH, Thompson AJ
Advancing trial design in progressive multiple sclerosis.
Mult Scler. 2017;23:1571-1572.
PubMed Text format

MOCCIA M, de Stefano N, Barkhof F
Imaging outcome measures for progressive multiple sclerosis trials.
Mult Scler. 2017;23:1614-1626.
PubMed Text format Abstract available

PICHLER A, Khalil M, Langkammer C, Pinter D, et al
The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517736149. doi: 10.1177/1352458517736149.
PubMed Text format Abstract available

GLAZER CH, Tottenborg SS, Giwercman A, Brauner EV, et al
Male factor infertility and risk of multiple sclerosis: A register-based cohort study.
Mult Scler. 2017 Oct 1:1352458517734069. doi: 10.1177/1352458517734069.
PubMed Text format Abstract available

TINELLI M, Kanavos P, Efthymiadou O, Visintin E, et al
Using IMPrESS to guide policy change in multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517737388. doi: 10.1177/1352458517737388.
PubMed Text format Abstract available

DONADIEU M, Le Fur Y, Maarouf A, Gherib S, et al
Metabolic counterparts of sodium accumulation in multiple sclerosis: A whole brain 23Na-MRI and fast 1H-MRSI study.
Mult Scler. 2017 Oct 1:1352458517736146. doi: 10.1177/1352458517736146.
PubMed Text format Abstract available

FLEMING J, Hernandez G, Hartman L, Maksimovic J, et al
Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial.
Mult Scler. 2017 Oct 1:1352458517736377. doi: 10.1177/1352458517736377.
PubMed Text format Abstract available

BSTEH G, Hegen H, Teuchner B, Amprosi M, et al
Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517740216. doi: 10.1177/1352458517740216.
PubMed Text format Abstract available

LEAVITT VM, Blanchard AR, Guo CY, Gelernt E, et al
Aspirin is an effective pretreatment for exercise in multiple sclerosis: A double-blind randomized controlled pilot trial.
Mult Scler. 2017 Oct 1:1352458517739138. doi: 10.1177/1352458517739138.
PubMed Text format Abstract available

DEKKER I, Sombekke MH, Witte BI, Geurts JJ, et al
Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517736147. doi: 10.1177/1352458517736147.
PubMed Text format Abstract available

BOESEN F, Norgaard M, Trenel P, Rasmussen PV, et al
Longer term effectiveness of inpatient multidisciplinary rehabilitation on health-related quality of life in MS patients: a pragmatic randomized controlled trial - The Danish MS Hospitals Rehabilitation Study.
Mult Scler. 2017 Oct 1:1352458517735188. doi: 10.1177/1352458517735188.
PubMed Text format Abstract available

September 2017

TOBYNE SM, Ochoa WB, Bireley JD, Smith VM, et al
Cognitive impairment and the regional distribution of cerebellar lesions in multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517730132. doi: 10.1177/1352458517730132.
PubMed Text format Abstract available

FAZIA T, Pastorino R, Foco L, Han L, et al
Investigating multiple sclerosis genetic susceptibility on the founder population of east-central Sardinia via association and linkage analysis of immune-related loci.
Mult Scler. 2017 Sep 1:1352458517732841. doi: 10.1177/1352458517732841.
PubMed Text format Abstract available

HUPPKE P, Huppke B, Ellenberger D, Rostasy K, et al
Therapy of highly active pediatric multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517732843. doi: 10.1177/1352458517732843.
PubMed Text format Abstract available

LANZILLO R, Cennamo G, Criscuolo C, Carotenuto A, et al
Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517729463. doi: 10.1177/1352458517729463.
PubMed Text format Abstract available

COMBER L, Quinn G, McGuigan C, Galvin R, et al
Medication usage and falls in people with multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517731912. doi: 10.1177/1352458517731912.
PubMed Text format Abstract available

MEINL I, Havla J, Hohlfeld R, Kumpfel T, et al
Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517731913. doi: 10.1177/1352458517731913.
PubMed Text format Abstract available

GIOVANNONI G, Wiendl H, Turner B, Umans K, et al
Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.
Mult Scler. 2017 Sep 1:1352458517729464. doi: 10.1177/1352458517729464.
PubMed Text format Abstract available

KAPPOS L, Arnold DL, Bar-Or A, Camm AJ, et al
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517728343. doi: 10.1177/1352458517728343.
PubMed Text format Abstract available

BISECCO A, Nardo FD, Docimo R, Caiazzo G, et al
Fatigue in multiple sclerosis: The contribution of resting-state functional connectivity reorganization.
Mult Scler. 2017 Sep 1:1352458517730932. doi: 10.1177/1352458517730932.
PubMed Text format Abstract available

CHARVET LE, Dobbs B, Shaw MT, Bikson M, et al
Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: Results from a randomized, sham-controlled trial.
Mult Scler. 2017 Sep 1:1352458517732842. doi: 10.1177/1352458517732842.
PubMed Text format Abstract available

August 2017

BRUNDIN L, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden.
Mult Scler. 2017;23.
PubMed Text format Abstract available

BATTAGLIA M, Kobelt G, Ponzio M, Berg J, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy.
Mult Scler. 2017;23.
PubMed Text format Abstract available

BERGER T, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria.
Mult Scler. 2017;23.
PubMed Text format Abstract available

DUBOIS B, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium.
Mult Scler. 2017;23.
PubMed Text format Abstract available

OREJA-GUEVARA C, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain.
Mult Scler. 2017;23.
PubMed Text format Abstract available

CALABRESE P, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland.
Mult Scler. 2017;23.
PubMed Text format Abstract available

UITDEHAAG B, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands.
Mult Scler. 2017;23.
PubMed Text format Abstract available

FLACHENECKER P, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany.
Mult Scler. 2017;23.
PubMed Text format Abstract available

KOBELT G, Eriksson J, Phillips G, Berg J, et al
The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms.
Mult Scler. 2017;23.
PubMed Text format Abstract available

PENTEK M, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary.
Mult Scler. 2017;23.
PubMed Text format Abstract available

BOYKO A, Kobelt G, Berg J, Boyko O, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia.
Mult Scler. 2017;23.
PubMed Text format Abstract available

RASMUSSEN PV, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark.
Mult Scler. 2017;23.
PubMed Text format Abstract available

LEBRUN-FRENAY C, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for France.
Mult Scler. 2017;23.
PubMed Text format Abstract available

THOMPSON A, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom.
Mult Scler. 2017;23.
PubMed Text format Abstract available

SELMAJ K, Kobelt G, Berg J, Orlewska E, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland.
Mult Scler. 2017;23.
PubMed Text format Abstract available

SA MJ, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal.
Mult Scler. 2017;23.
PubMed Text format Abstract available

HAVRDOVA E, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic.
Mult Scler. 2017;23.
PubMed Text format Abstract available

VERMOHLEN V, Schiller P, Schickendantz S, Drache M, et al
Hippotherapy for patients with multiple sclerosis: A multicenter randomized controlled trial (MS-HIPPO).
Mult Scler. 2017 Aug 1:1352458517721354. doi: 10.1177/1352458517721354.
PubMed Text format Abstract available

RUHRMANN S, Ewing E, Piket E, Kular L, et al
Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes.
Mult Scler. 2017 Aug 1:1352458517721356. doi: 10.1177/1352458517721356.
PubMed Text format Abstract available

LAROCCA NG, Hudson LD, Rudick R, Amtmann D, et al
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
Mult Scler. 2017 Aug 1:1352458517723718. doi: 10.1177/1352458517723718.
PubMed Text format Abstract available

VAVASOUR IM, Huijskens SC, Li DK, Traboulsee AL, et al
Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter.
Mult Scler. 2017 Aug 1:1352458517723717. doi: 10.1177/1352458517723717.
PubMed Text format Abstract available

BERGAMASCHI R, Cortese A, Pichiecchio A, Berzolari FG, et al
Air pollution is associated to the multiple sclerosis inflammatory activity as measured by brain MRI.
Mult Scler. 2017 Aug 1:1352458517726866. doi: 10.1177/1352458517726866.
PubMed Text format Abstract available

LOUAPRE C, Govindarajan ST, Gianni C, Madigan N, et al
Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7 T imaging.
Mult Scler. 2017 Aug 1:1352458517726382. doi: 10.1177/1352458517726382.
PubMed Text format Abstract available

SELLEBJERG F, Bornsen L, Ammitzboll C, Nielsen JE, et al
Defining active progressive multiple sclerosis.
Mult Scler. 2017 Aug 1:1352458517726592. doi: 10.1177/1352458517726592.
PubMed Text format Abstract available

ZIMMER P, Bloch W, Schenk A, Oberste M, et al
High-intensity interval exercise improves cognitive performance and reduces matrix metalloproteinases-2 serum levels in persons with multiple sclerosis: A randomized controlled trial.
Mult Scler. 2017 Aug 1:1352458517728342. doi: 10.1177/1352458517728342.
PubMed Text format Abstract available

SOLOMON AJ, Watts R, Ontaneda D, Absinta M, et al
Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.
Mult Scler. 2017 Aug 1:1352458517726383. doi: 10.1177/1352458517726383.
PubMed Text format Abstract available

AFOLABI D, Albor C, Zalewski L, Altmann DR, et al
Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
Mult Scler. 2017 Aug 1:1352458517726380. doi: 10.1177/1352458517726380.
PubMed Text format Abstract available

FAISSNER S, Mahjoub Y, Mishra M, Haupeltshofer S, et al
Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?
Mult Scler. 2017 Aug 1:1352458517728811. doi: 10.1177/1352458517728811.
PubMed Text format Abstract available

KALINCIK T, Jokubaitis V, Spelman T, Horakova D, et al
Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis.
Mult Scler. 2017 Aug 1:1352458517728812. doi: 10.1177/1352458517728812.
PubMed Text format Abstract available

BOVE R, Chitnis T, Cree BA, Tintore M, et al
SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.
Mult Scler. 2017 Aug 1:1352458517726657. doi: 10.1177/1352458517726657.
PubMed Text format Abstract available

GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan K, et al
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Mult Scler. 2017 Aug 1:1352458517727603. doi: 10.1177/1352458517727603.
PubMed Text format Abstract available

SEHR T, Proschmann U, Thomas K, Ziemssen T, et al
Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".
Mult Scler. 2017 Aug 1:1352458517726384. doi: 10.1177/1352458517726384.
PubMed Text format

LEURS CE, van Kempen ZL, Dekker I, Balk LJ, et al
Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
Mult Scler. 2017 Aug 1:1352458517726381. doi: 10.1177/1352458517726381.
PubMed Text format Abstract available

July 2017

MIGLIORE S, Curcio G, Couyoumdjian A, Ghazaryan A, et al
Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol.
Mult Scler. 2017 Jul 1:1352458517719149. doi: 10.1177/1352458517719149.
PubMed Text format Abstract available

KJOLHEDE T, Siemonsen S, Wenzel D, Stellmann JP, et al
Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?
Mult Scler. 2017 Jul 1:1352458517722645. doi: 10.1177/1352458517722645.
PubMed Text format Abstract available

TANAKA M, Kinoshita M, Tanaka K
Intermittent drug holidays in fingolimod therapy for multiple sclerosis.
Mult Scler. 2017 Jul 1:1352458517722647. doi: 10.1177/1352458517722647.
PubMed Text format

STAMPANONI BASSI M, Leocani L, Comi G, Iezzi E, et al
Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis?
Mult Scler. 2017 Jul 1:1352458517721358. doi: 10.1177/1352458517721358.
PubMed Text format Abstract available

ROLF L, Muris AH, Mathias A, Du Pasquier R, et al
Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Jul 1:1352458517722646. doi: 10.1177/1352458517722646.
PubMed Text format Abstract available

BALDASSARI LE, Salter AR, Longbrake EE, Cross AH, et al
Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS.
Mult Scler. 2017 Jul 1:1352458517721357. doi: 10.1177/1352458517721357.
PubMed Text format Abstract available

DUNN N, Juto A, Ryner M, Manouchehrinia A, et al
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
Mult Scler. 2017 Jul 1:1352458517720044. doi: 10.1177/1352458517720044.
PubMed Text format Abstract available

CANCELLI A, Cottone C, Giordani A, Migliore S, et al
Personalized, bilateral whole-body somatosensory cortex stimulation to relieve fatigue in multiple sclerosis.
Mult Scler. 2017 Jul 1:1352458517720528. doi: 10.1177/1352458517720528.
PubMed Text format Abstract available

RODRIGUEZ-LEAL FA, Haase R, Thomas K, Eisele JC, et al
Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
Mult Scler. 2017 Jul 1:1352458517720043. doi: 10.1177/1352458517720043.
PubMed Text format Abstract available

June 2017

CHOI IY, Lee P, Adany P, Hughes AJ, et al
In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517711568. doi: 10.1177/1352458517711568.
PubMed Text format Abstract available

SATTARNEZHAD N, Farrow S, Kimbrough D, Glanz B, et al
Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients.
Mult Scler. 2017 Jun 1:1352458517713667. doi: 10.1177/1352458517713667.
PubMed Text format Abstract available

LEE H, Nakamura K, Narayanan S, Brown R, et al
Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517715811. doi: 10.1177/1352458517715811.
PubMed Text format Abstract available

BOESEN MS, Magyari M, Koch-Henriksen N, Thygesen LC, et al
Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: A nationwide population-based incidence study.
Mult Scler. 2017 Jun 1:1352458517713669. doi: 10.1177/1352458517713669.
PubMed Text format Abstract available

PAKPOOR J, Seminatore B, Graves JS, Schreiner T, et al
Dietary factors and pediatric multiple sclerosis: A case-control study.
Mult Scler. 2017 Jun 1:1352458517713343. doi: 10.1177/1352458517713343.
PubMed Text format Abstract available

SALMEN A
Clinical commentary on "Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab".
Mult Scler. 2017 Jun 1:1352458517717810. doi: 10.1177/1352458517717810.
PubMed Text format

MULERO P, Auger C, Parolin L, Fonseca E, et al
Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.
Mult Scler. 2017 Jun 1:1352458517711569. doi: 10.1177/1352458517711569.
PubMed Text format Abstract available

FOLEY RW, Tagg NT, Schindler MK, Fenton KM, et al
Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517702533. doi: 10.1177/1352458517702533.
PubMed Text format Abstract available

DOBRYAKOVA E, Hulst HE, Spirou A, Chiaravalloti ND, et al
Fronto-striatal network activation leads to less fatigue in multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517717087. doi: 10.1177/1352458517717087.
PubMed Text format Abstract available

RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517719152. doi: 10.1177/1352458517719152.
PubMed Text format

YAP SM, McNicholas N, Hutchinson M, McGuigan C, et al
Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis - Not always self-limiting, fully reversible or predictable.
Mult Scler. 2017 Jun 1:1352458517719151. doi: 10.1177/1352458517719151.
PubMed Text format

WEYGANDT M, Wakonig K, Behrens J, Meyer-Arndt L, et al
Brain activity, regional gray matter loss, and decision-making in multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517717089. doi: 10.1177/1352458517717089.
PubMed Text format Abstract available

HIDALGO DE LA CRUZ M, d'Ambrosio A, Valsasina P, Pagani E, et al
Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517717807. doi: 10.1177/1352458517717807.
PubMed Text format Abstract available

RUANO L, Branco M, Portaccio E, Goretti B, et al
Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study.
Mult Scler. 2017 Jun 1:1352458517717341. doi: 10.1177/1352458517717341.
PubMed Text format Abstract available

BOZ C, Terzi M, Zengin Karahan S, Sen S, et al
Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517717806. doi: 10.1177/1352458517717806.
PubMed Text format Abstract available

May 2017

GOVEROVER Y, Chiaravalloti N, Genova H, DeLuca J, et al
A randomized controlled trial to treat impaired learning and memory in multiple sclerosis: The self-GEN trial.
Mult Scler. 2017 May 1:1352458517709955. doi: 10.1177/1352458517709955.
PubMed Text format Abstract available

BENEDICT RH, Cohan S, Lynch SG, Riester K, et al
Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
Mult Scler. 2017 May 1:1352458517707345. doi: 10.1177/1352458517707345.
PubMed Text format Abstract available

FREILICH J, Manouchehrinia A, Trusheim M, Baird LG, et al
Characterization of annual disease progression of multiple sclerosis patients: A population-based study.
Mult Scler. 2017 May 1:1352458517706252. doi: 10.1177/1352458517706252.
PubMed Text format Abstract available

ZEYDAN B, Lowe VJ, Schwarz CG, Przybelski SA, et al
Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.
Mult Scler. 2017 May 1:1352458517707346. doi: 10.1177/1352458517707346.
PubMed Text format Abstract available

SHINODA K, Matsushita T, Nakamura Y, Masaki K, et al
HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis.
Mult Scler. 2017 May 1:1352458517707067. doi: 10.1177/1352458517707067.
PubMed Text format Abstract available

SALTER A, Thomas NP, Tyry T, Cutter GR, et al
A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.
Mult Scler. 2017 May 1:1352458517711274. doi: 10.1177/1352458517711274.
PubMed Text format Abstract available

SUMOWSKI JF, Leavitt VM, Rocca MA, Inglese M, et al
Mesial temporal lobe and subcortical grey matter volumes differentially predict memory across stages of multiple sclerosis.
Mult Scler. 2017 May 1:1352458517708873. doi: 10.1177/1352458517708873.
PubMed Text format Abstract available

CAWLEY N, Tur C, Prados F, Plantone D, et al
Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.
Mult Scler. 2017 May 1:1352458517709954. doi: 10.1177/1352458517709954.
PubMed Text format Abstract available

BALK LJ, Coric D, Nij Bijvank JA, Killestein J, et al
Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.
Mult Scler. 2017 May 1:1352458517708463. doi: 10.1177/1352458517708463.
PubMed Text format Abstract available

PRINEAS JW, Parratt JDE
Multiple sclerosis: Serum anti-CNS autoantibodies.
Mult Scler. 2017 May 1:1352458517706037. doi: 10.1177/1352458517706037.
PubMed Text format Abstract available

PALOTAI M, Mike A, Cavallari M, Strammer E, et al
Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis.
Mult Scler. 2017 May 1:1352458517711273. doi: 10.1177/1352458517711273.
PubMed Text format Abstract available

MARINO M, Frisullo G, Di Sante G, Samengo DM, et al
Low reliability of anti-KIR4.183-120 peptide auto-antibodies in multiple sclerosis patients.
Mult Scler. 2017 May 1:1352458517711275. doi: 10.1177/1352458517711275.
PubMed Text format Abstract available

REDONDO J, Sarkar P, Kemp K, Virgo PF, et al
Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.
Mult Scler. 2017 May 1:1352458517711276. doi: 10.1177/1352458517711276.
PubMed Text format Abstract available

BIBERACHER V, Schmidt P, Selter RC, Pernpeinter V, et al
Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters.
Mult Scler. 2017 May 1:1352458517712078. doi: 10.1177/1352458517712078.
PubMed Text format Abstract available

SMOOT K, Spinelli KJ, Stuchiner T, Lucas L, et al
Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
Mult Scler. 2017 May 1:1352458517709956. doi: 10.1177/1352458517709956.
PubMed Text format Abstract available

TORTORELLA C, Direnzo V, Ruggieri M, Zoccolella S, et al
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.
Mult Scler. 2017 May 1:1352458517711774. doi: 10.1177/1352458517711774.
PubMed Text format Abstract available

VAN DER VUURST DE VRIES RM, van den Dorpel JJ, Mescheriakova JY, Runia TF, et al
Fatigue after a first attack of suspected multiple sclerosis.
Mult Scler. 2017 May 1:1352458517709348. doi: 10.1177/1352458517709348.
PubMed Text format Abstract available

VAN DEN AKKER LE, Beckerman H, Collette EH, Twisk JW, et al
Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial.
Mult Scler. 2017 May 1:1352458517709361. doi: 10.1177/1352458517709361.
PubMed Text format Abstract available

HEINE M, Verschuren O, Hoogervorst EL, van Munster E, et al
Does aerobic training alleviate fatigue and improve societal participation in patients with multiple sclerosis? A randomized controlled trial.
Mult Scler. 2017 May 1:1352458517696596. doi: 10.1177/1352458517696596.
PubMed Text format Abstract available

BLIKMAN LJ, van Meeteren J, Twisk JW, de Laat FA, et al
Effectiveness of energy conservation management on fatigue and participation in multiple sclerosis: A randomized controlled trial.
Mult Scler. 2017 May 1:1352458517702751. doi: 10.1177/1352458517702751.
PubMed Text format Abstract available

KAPPOS L, Butzkueven H, Wiendl H, Spelman T, et al
Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
Mult Scler. 2017 May 1:1352458517709619. doi: 10.1177/1352458517709619.
PubMed Text format Abstract available

SORMANI MP
Why non-inferiority is more challenging than superiority?
Mult Scler. 2017;23:790-791.
PubMed Text format Abstract available

HOEPNER R, Kolb EM, Dahlhaus S, Hellwig K, et al
Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
Mult Scler. 2017;23:830-835.
PubMed Text format Abstract available

PITTERI M, Romualdi C, Magliozzi R, Monaco S, et al
Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study.
Mult Scler. 2017;23:848-854.
PubMed Text format Abstract available

VAN KEMPEN ZL, Leurs CE, Witte BI, de Vries A, et al
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
Mult Scler. 2017 May 1:1352458517708464. doi: 10.1177/1352458517708464.
PubMed Text format Abstract available

April 2017

COETZEE T, Thompson A
When are we going to take modifiable risk factors more seriously in multiple sclerosis?
Mult Scler. 2017;23:494-495.
PubMed Text format

AL-LOUZI O, Button J, Newsome SD, Calabresi PA, et al
Retrograde trans-synaptic visual pathway degeneration in multiple sclerosis: A case series.
Mult Scler. 2017 Apr 1:1352458516679035. doi: 10.1177/1352458516679035.
PubMed Text format Abstract available

SOLARI A, Giordano A, Patti F, Grasso MG, et al
Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458517704078. doi: 10.1177/1352458517704078.
PubMed Text format Abstract available

COHEN JA, Imrey PB, Planchon SM, Bermel RA, et al
Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458517703802. doi: 10.1177/1352458517703802.
PubMed Text format Abstract available

GIOVANNONI G, Tomic D, Bright JR, Havrdova E, et al
"No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458517703193. doi: 10.1177/1352458517703193.
PubMed Text format Abstract available

MORANDI E, Tarlinton RE, Tanasescu R, Gran B, et al
Human endogenous retroviruses and multiple sclerosis: Causation, association, or after-effect?
Mult Scler. 2017 Apr 1:1352458517704711. doi: 10.1177/1352458517704711.
PubMed Text format Abstract available

KLAUSER AM, Wiebenga OT, Eijlers AJ, Schoonheim MM, et al
Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458517702534. doi: 10.1177/1352458517702534.
PubMed Text format Abstract available

AMATO MP
The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders.
Mult Scler. 2017 Apr 1:1352458517705002. doi: 10.1177/1352458517705002.
PubMed Text format Abstract available

ZAMBON AA, Cecchetti G, Caso F, Santangelo R, et al
Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case.
Mult Scler. 2017 Apr 1:1352458517702550. doi: 10.1177/1352458517702550.
PubMed Text format Abstract available

CIAMPI E, Uribe-San-Martin R, Godoy-Santin J, Cruz JP, et al
Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.
Mult Scler. 2017 Apr 1:1352458517702968. doi: 10.1177/1352458517702968.
PubMed Text format Abstract available

POP R, Kipfer S
Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458517702535. doi: 10.1177/1352458517702535.
PubMed Text format Abstract available

PAREES I
Clinical commentary on "Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis" and "Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients".
Mult Scler. 2017 Apr 1:1352458517702555. doi: 10.1177/1352458517702555.
PubMed Text format Abstract available

BODINI B, Branzoli F, Poirion E, Garcia-Lorenzo D, et al
Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.
Mult Scler. 2017 Apr 1:1352458517698249. doi: 10.1177/1352458517698249.
PubMed Text format Abstract available

KOLBER P, Droby A, Roebroeck A, Goebel R, et al
A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458516683267. doi: 10.1177/1352458516683267.
PubMed Text format Abstract available

KILSDONK ID, Schoonheim M, Wattjes MP
In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?
Mult Scler. 2017 Apr 1:1352458517704924. doi: 10.1177/1352458517704924.
PubMed Text format

TOUSSAINT-DUYSTER LC, Wong YYM, Van der Cammen-van Zijp MH, Van Pelt-Gravesteijn D, et al
Fatigue and physical functioning in children with multiple sclerosis and acute disseminated encephalomyelitis.
Mult Scler. 2017 Apr 1:1352458517706038. doi: 10.1177/1352458517706038.
PubMed Text format Abstract available

HAGENS MH, Killestein J, Yaqub MM, van Dongen GA, et al
Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.
Mult Scler. 2017 Apr 1:1352458517704507. doi: 10.1177/1352458517704507.
PubMed Text format Abstract available

SORMANI MP
Indirect comparisons of treatment effects: Network meta-analyses.
Mult Scler. 2017;23:510-512.
PubMed Text format Abstract available

BOUDOT DE LA MOTTE M, Louapre C, Bertrand A, Reach P, et al
Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
Mult Scler. 2017;23:614-616.
PubMed Text format Abstract available

AIRAS L, Rissanen E, Rinne J
Imaging of microglial activation in MS using PET: Research use and potential future clinical application.
Mult Scler. 2017;23:496-504.
PubMed Text format Abstract available

HUM S, Lapierre Y, Scott SC, Duquette P, et al
Trajectory of MS disease course for men and women over three eras.
Mult Scler. 2017;23:534-545.
PubMed Text format Abstract available

D'SOUZA M, Yaldizli O, John R, Vogt DR, et al
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.
Mult Scler. 2017;23:597-603.
PubMed Text format Abstract available

VERMERSCH P, Hobart J, Dive-Pouletty C, Bozzi S, et al
Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?
Mult Scler. 2017;23:604-613.
PubMed Text format Abstract available

CIAMPI E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, et al
Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
Mult Scler. 2017;23:556-566.
PubMed Text format Abstract available

BROWNLEE WJ, Altmann DR, Alves Da Mota P, Swanton JK, et al
Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.
Mult Scler. 2017;23:665-674.
PubMed Text format Abstract available

SORMANI MP, Kappos L, Radue EW, Cohen J, et al
Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.
Mult Scler. 2017;23:656-664.
PubMed Text format Abstract available

SIGNORI A, Izquierdo G, Lugaresi A, Hupperts R, et al
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
Mult Scler. 2017 Apr 1:1352458517703800. doi: 10.1177/1352458517703800.
PubMed Text format Abstract available

March 2017

BOGIE JF, Boelen E, Louagie E, Delputte P, et al
CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.
Mult Scler. 2017 Mar 1:1352458517698759. doi: 10.1177/1352458517698759.
PubMed Text format Abstract available

PITAROKOILI K, Hellwig K, Lukas C, Gold R, et al
Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
Mult Scler. 2017;23:483-486.
PubMed Text format Abstract available

ARRAMBIDE G
Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis".
Mult Scler. 2017;23:486-487.
PubMed Text format

MARRIE RA
What is the risk of suicide in multiple sclerosis?
Mult Scler. 2017 Mar 1:1352458517699992. doi: 10.1177/1352458517699992.
PubMed Text format

KALSON-RAY S, Edan G, Leray E
An excessive risk of suicide may no longer be a reality for multiple sclerosis patients.
Mult Scler. 2017 Mar 1:1352458517699873. doi: 10.1177/1352458517699873.
PubMed Text format Abstract available

LEURS CE, Podlesniy P, Trullas R, Balk L, et al
Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.
Mult Scler. 2017 Mar 1:1352458517699874. doi: 10.1177/1352458517699874.
PubMed Text format Abstract available

ROCCA MA, Valsasina P, Leavitt VM, Rodegher M, et al
Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment.
Mult Scler. 2017 Mar 1:1352458517699875. doi: 10.1177/1352458517699875.
PubMed Text format Abstract available

RIO J, Rovira A, Tintore M, Otero-Romero S, et al
Disability progression markers over 6-12 years in interferon-beta-treated multiple sclerosis patients.
Mult Scler. 2017 Mar 1:1352458517698052. doi: 10.1177/1352458517698052.
PubMed Text format Abstract available

CORTESE M, Riise T, Bjornevik K, Myhr KM, et al
Body size and physical exercise, and the risk of multiple sclerosis.
Mult Scler. 2017 Mar 1:1352458517699289. doi: 10.1177/1352458517699289.
PubMed Text format Abstract available

RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
Mult Scler. 2017 Mar 1:1352458517699876. doi: 10.1177/1352458517699876.
PubMed Text format Abstract available

FEINSTEIN A, Pavisian B
Multiple sclerosis and suicide.
Mult Scler. 2017 Mar 1:1352458517702553. doi: 10.1177/1352458517702553.
PubMed Text format Abstract available

CHARVET LE, Shaw M, Frontario A, Langdon D, et al
Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing.
Mult Scler. 2017 Mar 1:1352458517701588. doi: 10.1177/1352458517701588.
PubMed Text format Abstract available

HOUTCHENS MK, Zapata LB, Curtis KM, Whiteman MK, et al
Contraception for women with multiple sclerosis: Guidance for healthcare providers.
Mult Scler. 2017 Mar 1:1352458517701314. doi: 10.1177/1352458517701314.
PubMed Text format Abstract available

RUGGIERI S, Fanelli F, Castelli L, Petsas N, et al
Lesion symptom map of cognitive-postural interference in multiple sclerosis.
Mult Scler. 2017 Mar 1:1352458517701313. doi: 10.1177/1352458517701313.
PubMed Text format Abstract available

TOURBAH A, Sedel F
Reply to the letter: Biotinidase deficiency masquerading as multiple sclerosis?
Mult Scler. 2017 Mar 1:1352458517702554. doi: 10.1177/1352458517702554.
PubMed Text format

WOLF B
Biotinidase deficiency masquerading as multiple sclerosis?
Mult Scler. 2017 Mar 1:1352458517702551. doi: 10.1177/1352458517702551.
PubMed Text format

GYLLENSTEN H, Wiberg M, Alexanderson K, Friberg E, et al
Comparing costs of illness of multiple sclerosis in three different years: A population-based study.
Mult Scler. 2017 Mar 1:1352458517702549. doi: 10.1177/1352458517702549.
PubMed Text format Abstract available

INEICHEN BV, Schneider MP, Hlavica M, Hagenbuch N, et al
High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis.
Mult Scler. 2017 Mar 1:1352458517703801. doi: 10.1177/1352458517703801.
PubMed Text format Abstract available

SORMANI MP
Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts.
Mult Scler. 2017;23:378-381.
PubMed Text format Abstract available

GRAVES JS, Chohan H, Cedars B, Arnow S, et al
Sex differences and subclinical retinal injury in pediatric-onset MS.
Mult Scler. 2017;23:447-455.
PubMed Text format Abstract available

YAP SM, McGuigan C
High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
Mult Scler. 2017 Mar 1:1352458517697909. doi: 10.1177/1352458517697909.
PubMed Text format

ENZINGER C
High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - NO.
Mult Scler. 2017 Mar 1:1352458516681505. doi: 10.1177/1352458516681505.
PubMed Text format

February 2017

HEMPEL S, Graham GD, Fu N, Estrada E, et al
A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517690271. doi: 10.1177/1352458517690271.
PubMed Text format Abstract available

HEMPEL S, Graham GD, Fu N, Estrada E, et al
A systematic review of modifiable risk factors in the progression of multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517690270. doi: 10.1177/1352458517690270.
PubMed Text format Abstract available

PRAVATA E, Rocca MA, Valsasina P, Riccitelli GC, et al
Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517692886. doi: 10.1177/1352458517692886.
PubMed Text format Abstract available

CARPENTER AF, Goodwin SJ, Bornstein PF, Larson AJ, et al
Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
Mult Scler. 2017;23:297-299.
PubMed Text format Abstract available

CAMERON MH, McMillan G
Methylphenidate is likely less effective than placebo for improving imbalance, walking, and fatigue in people with multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517692421. doi: 10.1177/1352458517692421.
PubMed Text format

SONNENBERG A, Ajdacic-Gross V
Similar birth-cohort patterns in Crohn's disease and multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517691620. doi: 10.1177/1352458517691620.
PubMed Text format Abstract available

BALCER LJ, Raynowska J, Nolan R, Galetta SL, et al
Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517690822. doi: 10.1177/1352458517690822.
PubMed Text format Abstract available

MOTL RW, Cohen JA, Benedict R, Phillips G, et al
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517690823. doi: 10.1177/1352458517690823.
PubMed Text format Abstract available

BENEDICT RH, DeLuca J, Phillips G, LaRocca N, et al
Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517690821. doi: 10.1177/1352458517690821.
PubMed Text format Abstract available

FEYS P, Lamers I, Francis G, Benedict R, et al
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517690824. doi: 10.1177/1352458517690824.
PubMed Text format Abstract available

HULST HE, Thompson AJ, Geurts JJ
The measure tells the tale: Clinical outcome measures in multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517690825. doi: 10.1177/1352458517690825.
PubMed Text format

SHOR N, Amador MD, Dormont D, Lubetzki C, et al
Involvement of peripheral III nerve in multiple sclerosis patient: Report of a new case and discussion of the underlying mechanism.
Mult Scler. 2017 Feb 1:1352458516687401. doi: 10.1177/1352458516687401.
PubMed Text format Abstract available

ROVIRA A
Peripheral nervous system involvement in multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517693469. doi: 10.1177/1352458517693469.
PubMed Text format

CORIC D, Balk LJ, Verrijp M, Eijlers A, et al
Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.
Mult Scler. 2017 Feb 1:1352458517694090. doi: 10.1177/1352458517694090.
PubMed Text format Abstract available

GIACOMINI E, Rizzo F, Etna MP, Cruciani M, et al
Thymosin-alpha1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.
Mult Scler. 2017 Feb 1:1352458517695892. doi: 10.1177/1352458517695892.
PubMed Text format Abstract available

GALAZKA G, Mycko MP, Selmaj I, Raine CS, et al
Multiple sclerosis: Serum-derived exosomes express myelin proteins.
Mult Scler. 2017 Feb 1:1352458517696597. doi: 10.1177/1352458517696597.
PubMed Text format Abstract available

MAILLEUX J, Vanmierlo T, Bogie JF, Wouters E, et al
Active liver X receptor signaling in phagocytes in multiple sclerosis lesions.
Mult Scler. 2017 Feb 1:1352458517696595. doi: 10.1177/1352458517696595.
PubMed Text format Abstract available

ROY S, Drake AS, Eizaguirre MB, Zivadinov R, et al
Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?
Mult Scler. 2017 Feb 1:1352458517695467. doi: 10.1177/1352458517695467.
PubMed Text format Abstract available

SCHWARTZ CE, Grover SA, Powell VE, Noguera A, et al
Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517695469. doi: 10.1177/1352458517695469.
PubMed Text format Abstract available

CACAO G, Santos E, Martins Silva A
Concurrent autoimmune hepatitis in multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517692885. doi: 10.1177/1352458517692885.
PubMed Text format Abstract available

GOLAN D, Doniger GM, Wissemann K, Zarif M, et al
The impact of subjective cognitive fatigue and depression on cognitive function in patients with multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517695470. doi: 10.1177/1352458517695470.
PubMed Text format Abstract available

ZECCA C, Merlini A, Disanto G, Rodegher M, et al
Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
Mult Scler. 2017 Feb 1:1352458517694089. doi: 10.1177/1352458517694089.
PubMed Text format Abstract available

KOBELT G, Thompson A, Berg J, Gannedahl M, et al
New insights into the burden and costs of multiple sclerosis in Europe.
Mult Scler. 2017 Feb 1:1352458517694432. doi: 10.1177/1352458517694432.
PubMed Text format Abstract available

WESNES K, Myhr KM, Riise T, Cortese M, et al
Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study.
Mult Scler. 2017 Feb 1:1352458517694088. doi: 10.1177/1352458517694088.
PubMed Text format Abstract available

PATEL VP, Walker LA, Feinstein A
Revisiting cognitive reserve and cognition in multiple sclerosis: A closer look at depression.
Mult Scler. 2017 Feb 1:1352458517692887. doi: 10.1177/1352458517692887.
PubMed Text format Abstract available

CLERICO M, De Mercanti S, Artusi CA, Durelli L, et al
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
Mult Scler. 2017 Feb 1:1352458516688350. doi: 10.1177/1352458516688350.
PubMed Text format Abstract available

SHEIKH-TAHA M, Corman LC
Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517694431. doi: 10.1177/1352458517694431.
PubMed Text format Abstract available

BACCHETTA F, Mathias A, Schluep M, Du Pasquier R, et al
Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Mult Scler. 2017;23:300-303.
PubMed Text format Abstract available

SORMANI MP, Bruzzi P
Estimating a treatment effect: Choosing between relative and absolute measures.
Mult Scler. 2017;23:197-200.
PubMed Text format Abstract available

SORMANI MP, Muraro PA, Saccardi R, Mancardi G, et al
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Mult Scler. 2017;23:201-204.
PubMed Text format Abstract available

January 2017

AMATO MP, Derfuss T, Hemmer B, Liblau R, et al
Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.
Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847.
PubMed Text format Abstract available

GONZALEZ TORRE JA, Cruz-Gomez AJ, Belenguer A, Sanchis-Segura C, et al
Hippocampal dysfunction is associated with memory impairment in multiple sclerosis: A volumetric and functional connectivity study.
Mult Scler. 2017 Jan 1:1352458516688349. doi: 10.1177/1352458516688349.
PubMed Text format Abstract available

MUNOZ MA, Kulick CG, Kortepeter CM, Levin RL, et al
Liver injury associated with dimethyl fumarate in multiple sclerosis patients.
Mult Scler. 2017 Jan 1:1352458516688351. doi: 10.1177/1352458516688351.
PubMed Text format Abstract available

MOTL RW, Mowry EM, Ehde DM, LaRocca NG, et al
Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities.
Mult Scler. 2017 Jan 1:1352458516687404. doi: 10.1177/1352458516687404.
PubMed Text format Abstract available

SUN H
Temperature dependence of multiple sclerosis mortality rates in the United States.
Mult Scler. 2017 Jan 1:1352458516688954. doi: 10.1177/1352458516688954.
PubMed Text format Abstract available

LEAVITT VM, Buyukturkoglu K, Inglese M, Sumowski JF, et al
Protective personality traits: High openness and low neuroticism linked to better memory in multiple sclerosis.
Mult Scler. 2017 Jan 1:1352458516685417. doi: 10.1177/1352458516685417.
PubMed Text format Abstract available

SONG J, Karrenbauer V, Manouchehrinia A, Almqvist C, et al
Similar familial risk in multiple sclerosis subgroups.
Mult Scler. 2017 Jan 1:1352458516684214. doi: 10.1177/1352458516684214.
PubMed Text format Abstract available

DE STEFANO N, Giorgio A, Battaglini M, De Leucio A, et al
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
Mult Scler. 2017 Jan 1:1352458517690269. doi: 10.1177/1352458517690269.
PubMed Text format Abstract available

MA AY, Vitorino RC, Hojjat SP, Mulholland AD, et al
The relationship between white matter fiber damage and gray matter perfusion in large-scale functionally defined networks in multiple sclerosis.
Mult Scler. 2017 Jan 1:1352458517691149. doi: 10.1177/1352458517691149.
PubMed Text format Abstract available

BJORNEVIK K, Chitnis T, Ascherio A, Munger KL, et al
Polyunsaturated fatty acids and the risk of multiple sclerosis.
Mult Scler. 2017 Jan 1:1352458517691150. doi: 10.1177/1352458517691150.
PubMed Text format Abstract available

GOPAL S, Mikulskis A, Gold R, Fox RJ, et al
Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
Mult Scler. 2017 Jan 1:1352458517690617. doi: 10.1177/1352458517690617.
PubMed Text format Abstract available

MANOUCHEHRINIA A, Westerlind H, Kingwell E, Zhu F, et al
Age Related Multiple Sclerosis Severity Score: Disability ranked by age.
Mult Scler. 2017 Jan 1:1352458517690618. doi: 10.1177/1352458517690618.
PubMed Text format Abstract available

DECARD BF, Thone J, Haghikia A, Bornke C, et al
Listeria rhombencephalitis mimicking a demyelinating event in an immunocompetent young patient.
Mult Scler. 2017;23:123-125.
PubMed Text format Abstract available

LAROCHELLE C, Metz I, Lecuyer MA, Terouz S, et al
Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.
Mult Scler. 2017;23:72-81.
PubMed Text format Abstract available

BURTON JM, Eliasziw M, Trufyn J, Tung C, et al
A prospective cohort study of vitamin D in optic neuritis recovery.
Mult Scler. 2017;23:82-93.
PubMed Text format Abstract available

HAAS J, Schneider K, Schwarz A, Korporal-Kuhnke M, et al
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
Mult Scler. 2017;23:114-118.
PubMed Text format Abstract available

KALINCIK T, Sormani MP
Reporting treatment outcomes in observational data: A fine balance.
Mult Scler. 2017;23:21-22.
PubMed Text format Abstract available

SORMANI MP
Subgroup analysis in MS trials.
Mult Scler. 2017;23:34-35.
PubMed Text format Abstract available

December 2016

MANOUCHEHRINIA A, Beiki O, Hillert J
Clinical course of multiple sclerosis: A nationwide cohort study.
Mult Scler. 2016 Dec 12. pii: 1352458516681197.
PubMed Text format Abstract available

BUDHRAM A, Parvathy S, Kremenchutzky M, Silverman M, et al
Breaking down the gut microbiome composition in multiple sclerosis.
Mult Scler. 2016 Dec 12. pii: 1352458516682105.
PubMed Text format Abstract available

KAPPOS L, Havrdova E, Giovannoni G, Khatri BO, et al
No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
Mult Scler. 2016 Dec 1:1352458516683266. doi: 10.1177/1352458516683266.
PubMed Text format Abstract available

CRISTOFANILLI M, Gratch D, Pagano B, McDermott K, et al
Transglutaminase-6 is an autoantigen in progressive multiple sclerosis and is upregulated in reactive astrocytes.
Mult Scler. 2016 Dec 1:1352458516684022. doi: 10.1177/1352458516684022.
PubMed Text format Abstract available

WIJNANDS JM, Kingwell E, Zhu F, Zhao Y, et al
Infection-related health care utilization among people with and without multiple sclerosis.
Mult Scler. 2016 Dec 1:1352458516681198. doi: 10.1177/1352458516681198.
PubMed Text format Abstract available

IKRAM MA, Vernooij MW, Roshchupkin GV, Hofman A, et al
Genetic susceptibility to multiple sclerosis: Brain structure and cognitive function in the general population.
Mult Scler. 2016 Dec 1:1352458516682104. doi: 10.1177/1352458516682104.
PubMed Text format Abstract available

BATISTA S, d'Almeida OC, Afonso A, Freitas S, et al
Impairment of social cognition in multiple sclerosis: Amygdala atrophy is the main predictor.
Mult Scler. 2016 Dec 1:1352458516680750. doi: 10.1177/1352458516680750.
PubMed Text format Abstract available

GHEZZI A
Randomized clinical trials (RCTs) in pediatric multiple sclerosis: Are they really necessary?
Mult Scler. 2016 Dec 1:1352458516684025. doi: 10.1177/1352458516684025.
PubMed Text format

November 2016

GOLDMAN MD, Ward MD, Motl RW, Jones DE, et al
Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale.
Mult Scler. 2016 Nov 30. pii: 1352458516680749.
PubMed Text format Abstract available

HARRISON AM, das Nair R, Moss-Morris R
Operationalising cognitive fatigability in multiple sclerosis: A Gordian knot that can be cut?
Mult Scler. 2016 Nov 30. pii: 1352458516681862.
PubMed Text format Abstract available

SEPULVEDA M, Fernandez-Diez B, Martinez-Lapiscina EH, Llufriu S, et al
Impairment of decision-making in multiple sclerosis: A neuroeconomic approach.
Mult Scler. 2016 Nov 30. pii: 1352458516682103.
PubMed Text format Abstract available

DEVORAK J, Mokry LE, Morris JA, Forgetta V, et al
Large differences in adiponectin levels have no clear effect on multiple sclerosis risk: A Mendelian randomization study.
Mult Scler. 2016 Nov 30. pii: 1352458516681196.
PubMed Text format Abstract available

DATTA G, Violante IR, Scott G, Zimmerman K, et al
Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis.
Mult Scler. 2016 Nov 30. pii: 1352458516681504.
PubMed Text format Abstract available

VOORTMAN MM, Stojakovic T, Pirpamer L, Jehna M, et al
Prognostic value of free light chains lambda and kappa in early multiple sclerosis.
Mult Scler. 2016 Nov 29. pii: 1352458516681503.
PubMed Text format Abstract available

VENTURA RE, Antezana AO, Bacon T, Kister I, et al
Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans.
Mult Scler. 2016 Nov 29. pii: 1352458516679894.
PubMed Text format Abstract available

ROY S, Frndak S, Drake AS, Irwin L, et al
Differential effects of aging on motor and cognitive functioning in multiple sclerosis.
Mult Scler. 2016 Nov 24. pii: 1352458516679036.
PubMed Text format Abstract available

VAN DIJK PA, Kirk-Brown AK, Taylor B, van der Mei I, et al
Closing the gap: Longitudinal changes in employment for Australians with multiple sclerosis.
Mult Scler. 2016 Nov 24. pii: 1352458516678934.
PubMed Text format Abstract available

ARROYO GONZALEZ R, Kita M, Crayton H, Havrdova E, et al
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Mult Scler. 2016 Nov 24. pii: 1352458516677589.
PubMed Text format Abstract available

ABDOLLAHPOUR I, Nedjat S, Sahraian MA, Mansournia MA, et al
Waterpipe smoking associated with multiple sclerosis: A population-based incident case-control study.
Mult Scler. 2016 Nov 10. pii: 1352458516677867.
PubMed Text format Abstract available

CARLING A, Forsberg A, Gunnarsson M, Nilsagard Y, et al
CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled pilot study.
Mult Scler. 2016 Nov 10. pii: 1352458516677591.
PubMed Text format Abstract available

SACCA F, Costabile T, Carotenuto A, Lanzillo R, et al
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests.
Mult Scler. 2016 Nov 3. pii: 1352458516677592.
PubMed Text format Abstract available

MIKOLAJCZAK J, Zimmermann H, Kheirkhah A, Kadas EM, et al
Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density.
Mult Scler. 2016 Nov 3. pii: 1352458516677590.
PubMed Text format Abstract available

CHATAWAY J
Biotin in progressive multiple sclerosis: A new lead?
Mult Scler. 2016;22:1640-1641.
PubMed Text format

GABILONDO I, Rilo O, Ojeda N, Pena J, et al
The influence of posterior visual pathway damage on visual information processing speed in multiple sclerosis.
Mult Scler. 2016 Nov 1:1352458516676642. doi: 10.1177/1352458516676642.
PubMed Text format Abstract available

CARUANA P, Lemmert K, Ribbons K, Lea R, et al
Natural killer cell subpopulations are associated with MRI activity in a relapsing-remitting multiple sclerosis patient cohort from Australia.
Mult Scler. 2016 Nov 1:1352458516679267. doi: 10.1177/1352458516679267.
PubMed Text format Abstract available

October 2016

PLANCHE V, Ruet A, Coupe P, Lamargue-Hamel D, et al
Hippocampal microstructural damage correlates with memory impairment in clinically isolated syndrome suggestive of multiple sclerosis.
Mult Scler. 2016 Oct 25. pii: 1352458516675750.
PubMed Text format Abstract available

BSTEH G, Feige J, Ehling R, Auer M, et al
Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
Mult Scler. 2016 Oct 20. pii: 1352458516675751.
PubMed Text format Abstract available

D'AMBROSIO A, Pagani E, Riccitelli GC, Colombo B, et al
Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis.
Mult Scler. 2016 Oct 19. pii: 1352458516674567.
PubMed Text format Abstract available

KAVALIUNAS A, Manouchehrinia A, Stawiarz L, Ramanujam R, et al
Importance of early treatment initiation in the clinical course of multiple sclerosis.
Mult Scler. 2016 Oct 17. pii: 1352458516675039.
PubMed Text format Abstract available

PIETROBONI AM, Schiano di Cola F, Scarioni M, Fenoglio C, et al
CSF beta-amyloid as a putative biomarker of disease progression in multiple sclerosis.
Mult Scler. 2016 Oct 17. pii: 1352458516674566.
PubMed Text format Abstract available

RUANO L, Portaccio E, Goretti B, Niccolai C, et al
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes.
Mult Scler. 2016 Oct 13. pii: 1352458516674367.
PubMed Text format Abstract available

WICKSTROM A, Fagerstrom M, Wickstrom L, Granasen G, et al
The impact of adjusted work conditions and disease-modifying drugs on work ability in multiple sclerosis.
Mult Scler. 2016 Oct 6. pii: 1352458516671818.
PubMed Text format Abstract available

AHMAD H, Taylor BV, van der Mei I, Colman S, et al
The impact of multiple sclerosis severity on health state utility values: Evidence from Australia.
Mult Scler. 2016 Oct 3. pii: 1352458516672014.
PubMed Text format Abstract available

LUBRINI G, Rios Lago M, Perianez JA, Tallon Barranco A, et al
The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis.
Mult Scler. 2016;22:1607-1615.
PubMed Text format Abstract available

ARNETT P
Lubrini et al.'s study, "The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis".
Mult Scler. 2016;22:1512-1513.
PubMed Text format

September 2016

MOBERG JY, Laursen B, Koch-Henriksen N, Thygesen LC, et al
Employment, disability pension and income for children with parental multiple sclerosis.
Mult Scler. 2016 Sep 28. pii: 1352458516672016.
PubMed Text format Abstract available

BOESCHOTEN RE, Dekker J, Uitdehaag BM, Beekman AT, et al
Internet-based treatment for depression in multiple sclerosis: A randomized controlled trial.
Mult Scler. 2016 Sep 28. pii: 1352458516671820.
PubMed Text format Abstract available

RIBBONS K, Lea R, Tiedeman C, Mackenzie L, et al
Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: A 50-year study.
Mult Scler. 2016 Sep 28. pii: 1352458516671819.
PubMed Text format Abstract available

SCHLEMM L, Chien C, Bellmann-Strobl J, Dorr J, et al
Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients.
Mult Scler. 2016 Sep 27. pii: 1352458516670738.
PubMed Text format Abstract available

GAFSON A, Craner MJ, Matthews PM
Personalised medicine for multiple sclerosis care.
Mult Scler. 2016 Sep 26. pii: 1352458516672017.
PubMed Text format Abstract available

BJORNEVIK K, Riise T, Bostrom I, Casetta L, et al
Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study.
Mult Scler. 2016 Sep 23. pii: 1352458516671028.
PubMed Text format Abstract available

COLLIGAN E, Metzler A, Tiryaki E
Shared decision-making in multiple sclerosis: A review.
Mult Scler. 2016 Sep 23. pii: 1352458516671204.
PubMed Text format Abstract available

HENGSTMAN GJ
Controversies in MS: All relapsing multiple sclerosis patients should be managed at a specialist clinic - Combine the best of two worlds!
Mult Scler. 2016 Sep 21. pii: 1352458516670737.
PubMed Text format

LANDFELDT E, Castelo-Branco A, Svedbom A, Lofroth E, et al
Sick leave and disability pension before and after diagnosis of multiple sclerosis.
Mult Scler. 2016 Sep 20. pii: 1352458516667567.
PubMed Text format Abstract available

CHOI IY, Lee P, Hughes AJ, Denney DR, et al
Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis.
Mult Scler. 2016 Sep 12. pii: 1352458516669441.
PubMed Text format Abstract available

ORPEZ-ZAFRA T, Pavia J, Hurtado-Guerrero I, Pinto-Medel MJ, et al
Decreased soluble IFN-beta receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.
Mult Scler. 2016 Sep 9. pii: 1352458516667564.
PubMed Text format Abstract available

HAKOBYAN S, Luppe S, Evans DR, Harding K, et al
Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.
Mult Scler. 2016 Sep 9. pii: 1352458516669002.
PubMed Text format Abstract available

NELSON F, Akhtar MA, Zuniga E, Perez CA, et al
Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosis.
Mult Scler. 2016 Sep 9. pii: 1352458516666186.
PubMed Text format Abstract available

August 2016

VERMERSCH P, Smets L, Gold R
Conclusions: Calls to action for improving the life of MS patients and their families.
Mult Scler. 2016;22.
PubMed Text format Abstract available

VERMERSCH P, Faller A, Czarnota-Szalkowska D, Meesen B, et al
The patient's perspective: How to create awareness for improving access to care and treatment of MS patients?
Mult Scler. 2016;22.
PubMed Text format Abstract available

May 2016

UHER T, Havrdova E, Sobisek L, Krasensky J, et al
Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
Mult Scler. 2016 May 26. pii: 1352458516650525.
PubMed Text format Abstract available

April 2016

MODVIG S, Degn M, Sander B, Horwitz H, et al
Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis.
Mult Scler. 2016;22:590-8.
PubMed Text format Abstract available

HADHOUM N, Hodel J, Defoort-Dhellemmes S, Duhamel A, et al
Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss.
Mult Scler. 2016;22:649-58.
PubMed Text format Abstract available

NEMECEK A, Zimmermann H, Rubenthaler J, Fleischer V, et al
Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression.
Mult Scler. 2016;22:483-93.
PubMed Text format Abstract available

March 2016

BEVER CT JR, Wallin MT
Tribute to John F. Kurtzke, MD, FACP, FAAN: 1926-2015.
Mult Scler. 2016;22:267-8.
PubMed Text format

ENZINGER C, Pinter D, Rocca MA, De Luca J, et al
Longitudinal fMRI studies: Exploring brain plasticity and repair in MS.
Mult Scler. 2016;22:269-78.
PubMed Text format Abstract available

PEKCEVIK Y, Mitchell CH, Mealy MA, Orman G, et al
Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
Mult Scler. 2016;22:302-11.
PubMed Text format Abstract available

MAKHANI N, Banwell B, Tellier R, Yea C, et al
Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination.
Mult Scler. 2016;22:385-8.
PubMed Text format Abstract available

VAN SCHEPENDOM J, Gielen J, Laton J, Nagels G, et al
Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
Mult Scler. 2016;22:389-92.
PubMed Text format Abstract available

February 2016

JARIUS S, Metz I, Konig FB, Ruprecht K, et al
Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case.
Mult Scler. 2016 Feb 11. pii: 1352458515622986.
PubMed Text format Abstract available

BERGAMASCHI R, Montomoli C
Modeling the course and outcomes of MS is statistical twaddle--No.
Mult Scler. 2016;22:142-4.
PubMed Text format

BEAUCHEMIN P, Carruthers R
MS arising during Tocilizumab therapy for rheumatoid arthritis.
Mult Scler. 2016;22:254-6.
PubMed Text format Abstract available

FERNANDEZ-CARBONELL C, Vargas-Lowy D, Musallam A, Healy B, et al
Clinical and MRI phenotype of children with MOG antibodies.
Mult Scler. 2016;22:174-84.
PubMed Text format Abstract available

HUPPERTS R, Lycke J, Short C, Gasperini C, et al
Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
Mult Scler. 2016;22:212-21.
PubMed Text format Abstract available

January 2016

SASTRE-GARRIGA J, Wiendl H
Highlights from the 31st ECTRIMS congress - Barcelona 2015.
Mult Scler. 2016;22:7-10.
PubMed Text format

REINGOLD SC, Lublin FD
William Austin Sibley, MD (1925-2015).
Mult Scler. 2016;22:11-2.
PubMed Text format

FREEDMAN MS
Are we in need of NEDA?
Mult Scler. 2016;22:5-6.
PubMed Text format

ZAJDA M, Kazmierczak B, Zakrzewska-Pniewska B
Aquaporin-4: A novel diagnostic biomarker for seronegative neuromyelitis optica.
Mult Scler. 2016;22:125-6.
PubMed Text format

November 2015

WATTJES MP, Wijburg MT, Vennegoor A, Witte BI, et al
Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
Mult Scler. 2015 Nov 12. pii: 1352458515615225.
PubMed Text format Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: